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Metabolic Reprogramming of Pancreatic Ductal
Adenocarcinoma Cells In Response To Chronic Low pH Stress
Jaime Abrego, Ph.D.
University of Nebraska Medical Center, 2017

Supervisor: Pankaj K. Singh, Ph.D.
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of all
cancers with a 5-year survival rate of only 8.2%. This is because PDAC is diagnosed in
its advanced stages and is characterized by radio and chemotherapy resistance.
Aggressiveness of PDAC tumors is attributed to its high metabolic phenotype, which is
characterized by increased glycolysis rate and lactate secretion, while oxidative
metabolism is reduced. These metabolic features are required to fulfill the biosynthetic
demands of proliferating PDAC cells. However, this increase in metabolic activity results
in acidification of the extracellular space because the dense fibrotic stroma of PDAC
tumors limits venting of protons into the vasculature thereby creating a chronic low pH
microenvironment. Little is known regarding the physiology and metabolism of cancer
cells enduring chronic low pH exposure.
To demonstrate effects of low pH, PDAC cells were cultured in low pH 6.9~7.0 to
establish chronic low pH as it occurs in tumors. These cells were compared to cells in
physiological pH of 7.4, which is also the pH of cell culture, in order to evaluate
physiological differences between these pH values. In these experiments, it was
observed that cells in low pH have reduced clonogenic capacity and undergo a
metabolic shift to oxidative metabolism that is supported by an increase in glutamine
uptake. These observations exhibit a robust contrast to PDAC cells in control pH
conditions that are highly glycolytic. Furthermore, in low pH there is increased
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transcription of the GOT1 enzyme, which mediates metabolic flux through the noncanonical glutamine metabolic pathway that allows synthesis of other metabolic
substrates from glutamine. Upon shRNA-mediated depletion of GOT1, survival of PDAC
cells in low pH was significantly impaired due to increase in ROS to cytotoxic levels.
However, supplementing transfected clones with GOT1 metabolic product, oxaloacetate,
resulted in growth rescue and reduction in ROS levels. Thus, in chronic low pH stress
PDAC cells up-regulate non-canonical glutamine metabolism through increased
transcription of GOT1, which allows PDAC cells to generate energy and metabolic cofactors to suppress cytotoxic ROS levels. Low pH is a universal feature of the PDAC
tumor microenvironment and further dissection of metabolic adaptations to
microenvironment conditions will result in more effective therapy for PDAC.
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Chapter 1
Introduction:
The Evolution Of PDAC And Its Acidic
Tumor Microenvironment
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Incidence of Pancreatic Ductal Adenocarcinoma
According to the American Cancer society, the estimate of new cases of
pancreatic cancer in 2017 is 53,670 and the number of estimated deaths is 43,090 [1, 2].
Needless to say, the 5-year survival rate is also very low at 8.2%, figure 1 [1, 2]. These
grim statistics have remained virtually unchanged over the past two decades. For this
reason, a diagnosis of pancreatic ductal adenocarcinoma (PDAC), the most common
type of pancreatic cancer representing 90% of all pancreatic cancers, is synonymous of
a death sentence as it carries one of the most dismal prognoses in all of medicine [3].
Poor disease outcome can be attributed to the lack of specific symptoms and limitation
in diagnostic methods allowing PDAC to elude detection during its formative stages; as a
result, PDAC is typically diagnosed in its advanced stages [4]. Currently, the only
reasonable hope of cure is through surgical resection, which in itself is a life-threatening
procedure, but rarely a curative end point is achieved due to disease spread and
recurrence [5]. Non-invasive procedures include radiation therapy and chemotherapy;
however, improvement of long-term survival is minimal due to pronounced PDAC
therapy resistance [6]. Thus, most treatments are palliative with the goal of improving the
quality of life in patients [6]. Alarmingly, the incidence of PDAC is expected to double
within the next 15 years [6]. For this reason, there is desperate need to understand the
complex biology of PDAC carcinogenesis in order to identify more effective therapeutic
approaches and improve patient survival.

Development of Pancreatic Ductal Adenocarcinoma
Acquisition of Oncogenic Mutations
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A basic tenet of Natural Selection is the constant occurrence of purposeless
mutations that increase genetic variability on which selection forces act. For a mutation
to occur, a complete cell division cycle must take place. Human DNA polymerases have
an error at a rate of 1x10-9 per base on each replication round [7-9]. Therefore,
statistically speaking, three single nucleotide variants occur per replication cycle of
somatic cells. Considering the human haploid genome is 3x109 base pairs
long and that the number of cells in an adult body is approximately 1014, mutations are
likely to occur at any time [8]. However, mathematical models predict that the
emergence of new strategies (phenotypes) in individual cells during tissue turnover does
not improve fitness and cancer requires more steps [10, 11]. Furthermore, not all cells in
the body are actively replicating this includes acinar and ductal cells of the adult
pancreas where PDAC originates [12, 13]. Thus, by simple chance alone, the incidence
of PDAC is rare, but if PDAC is to develop the initial mutation must be fixed to the
normal tissue landscape in order to hide from pathologic response such as tissue growth
constraints and immune responses that would lead to senescence and/or apoptosis.
This will allow the pre-malignant phenotype to proliferate giving more opportunities for its
clones to gain additional genomic instability that will lead to cancer, i.e. PDAC
signature. Perhaps, this explains the time frame between initial mutation, which occurs
at minimum two decades, and PDAC diagnosis [13]. The median age for diagnosis
of PDAC is 71 and 75% of cases are diagnosed between the ages of 55 and 84 [2, 3,
13]. Recent statistical analyses of various cancer types, including PDAC, calculated
high risk due to a strong correlation with aging and the predicted number of normal stem
cell divisions [14, 15]. However, there is much debate to describe links for PDAC
induction due to intrinsic factors, carcinogens, and non-cancerous pathophysiology of
cancer.
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Intrinsic factors occur because of chance events such as failure in genetic
replication, but this event is very unlikely in healthy patients. The most common intrinsic
factors that increase PDAC risk are familial traits where gene variants involved in DNA
double-strand break repair such as BRCA1, BRCA2, PALB2, FANCC, FANCG, and
ATM [16]. Understandably, defective DNA repair mechanism would increase genetic
instability and chances for somatic mutations to occur. Familial variants affecting tumor
suppressors also have robust incidence with PDAC. For example, germline mutations to
CDKN2A that encodes two proteins that regulate cell cycle progression these are
p16INK4A and p19ARF [16]. Carcinogens that damage the genome or alter metabolic
functions, as well as, tissue inflammation, cell turnover due to idiopathic diseases, and
organ specific disease all account for extrinsic factors of high PDAC risk [17]. It has been
demonstrated extensively that continuous exposure to proinflammatory agents increases ROS levels that promote DNA damage [18]. Inflammation
of the pancreas, also known as pancreatitis, caused by alcohol abuse and
smoking is associated high PDAC risk [19, 20]. Similarly, patients diagnosed with PDAC
are often diagnosed with diabetes type II (hyperinsulemia) and are classified as obese;
both of these conditions are associated with chronic inflammation of the pancreas [21].
Although it is unclear the mechanism of cooperation between genomic alterations and
tissue damage, both of these cause initial events leading to PDAC. In the context of
PDAC evolution, it is likely that the initial mutation occurs randomly, becomes fixed to
tissue landscape, and awaits for tissue damage to induce other genomic alterations and
evolve to PDAC [10, 14]. Thus, one could argue that the initial mutation is caused
intrinsically or by exposure to carcinogens and life style choices such as diet and alcohol
abuse will increase pancreatic burden paving the way for somatic evolution of PDAC.
Therefore, healthy status and normal function of the pancreas is critical in holding back
PDAC. Table 1A and Table 1B highlight intrinsic and extrinsic PDAC risk factors.
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Pancreatic Ductal Cell Function
The pancreas is a glandular organ of the digestive and endocrine systems
located in the abdominal cavity behind the stomach [22]. The histological features of the
pancreas are easily distinguishable under the microscope. Pancreas tissue with
endocrine role is arranged in clusters called pancreatic islets and constitutes about 1 to
2% of the total pancreas volume [22]. The critical metabolic hormones for metabolic
response, insulin and glucagon, are produced by beta and alpha cells, respectively, in
pancreatic islets [5]. The rest of the pancreas functions as part of the exocrine digestive
system composed of exocrine and ductal epithelium [22]. Acinar exocrine cells of the
pancreas, form clusters called acini, for the berry-like sac architecture [5]. This hollow
structure formed by acinar cells converges with epithelial cells of the pancreas to form a
ductal system designed for the delivery of digestive enzymes to the duodenum [5, 22].
The enzymes secreted by acini are lipase, proteases, and nucleases; while the ductal
cells secrete large amounts of sodium bicarbonate (NaHCO3) [22, 23].
Pancreatic cancers develop 95% of the time from exocrine cells and most
commonly from ductal cells 85-95% (PDAC), while cancer from acinar cells and
endocrine both represent less than 5% [22]. This is likely because more progenitor cells
are needed to replace the dispensable epithelial cells lining the pancreatic ducts
because ductal epithelium is exposed to more stress and thus progenitor cells undergo
more replication cycles increasing the chance for acquiring mutations. Some ambiguity
in PDAC origin exists because acinar cells are known to undergo acinar-ductal
metaplasia in pre-malignant lesions through increased expression of KRAS and
pancreatic progenitor cell transcription factors SOX9 and PDX1 [24]. Interestingly,
pancreatic cancers of exocrine origin are much more aggressive than pancreatic
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endocrine [25]. Thus, the function of pancreas exocrine and its condition in pathologic
circumstances must be addressed to learn more about PDAC initiation.
In normal conditions the pancreatic ductal cells secrete up to 140mM of sodium
bicarbonate, which is useful to neutralize the acid chime that enters the duodenum [23].
Interesting research on inhibition of bicarbonate release by ductal cells shows to be
reduced upon enzyme release by acinar cells while acinar secretion of chloride and ATP
has been demonstrated to stimulate ductal bicarbonate secretion [23]. Furthermore,
recent findings show that acinar exocytosis causes a significant acid load into the ductal
cavity thereby decreasing the pH by up to 1 unit [26]. Normally the pH in duct fluid is 8,
figure 2 [26]. Therefore, pH control by ductal cells is critical for tissue homeostasis, as
decease in pH has been shown to induce inflammation [23]. This has been
demonstrated in animal models where induction of pancreatitis by cerulein treatment
lowers the pH of ductal fluid [23, 27]. Similar findings have been noticed in drug
treatments, acid injections to the pancreas in experimental pancreatitis mouse models,
and in mutations affecting mitochondrial function that cause lactic acidosis [28].
Interestingly, ethanol exposure has been shown to decrease blood flow to the pancreas
by up to 60% causing hypoxic response and drop in pancreatic tissue extracellular pH
(pHe) to 7.1 [29]. This study highlights the role of the pancreatic ductal cells in blood pH
homeostasis by removing CO2 (metabolic acid) and converting it to bicarbonate that is
then used to regulate the pH of ductal fluid. Furthermore, idiopathic diseases affecting
blood flow may damage the pancreas indirectly by altering pH dynamics. Interestingly,
approximately 75% of PDAC tumors occur in the head of the pancreas where it links to
the duodenum. Therefore, bicarbonate secretion from ductal cells is critical to buffer the
pH from stomach acids and acinar secretions. These observations show how critical
bicarbonate secretions from ductal cells are for pH regulation for normal exocrine tissue
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function, as lowering of the pH increases risk of pancreatitis, which in turn increases risk
for PDAC greatly [30].
Pancreatic Ductal Adenocarcinoma as an Evolutionary Process
Solid tumors, such as PDAC, appear to progress in a stepwise manner. The first
step is acquisition of driving mutations, followed by clonal expansion from an initial
malignant cell, and third is local invasion and metastasis. Intriguingly enough,
progression of PDAC drastically affects the physical features of its tumor
microenvironment (TME) characterized by hypoxia, acidosis, and high interstitial
pressure [31]. However, the harsh conditions in the TME do not appear to oppose
carcinogenesis, instead, it seems to promote fitness of the tumor cells promoting
acquisition of phenotypes that promote cancer aggressiveness. Throughout this
introductory chapter, I will address carcinogenesis of PDAC as if it were a process
subjected to Darwinian evolutionary processes with the goal of instigating novel insights
and opportunities for study.
The model of Natural Selection, as proposed by Charles Darwin, is simply
defined by the differential rates of survival and reproduction due to differences in
phenotype of competing species [32]. These rules impose that the carrier of the fittest
phenotype will get to survive, reproduce, and pass on the given trait to offspring. The
process of evolution can be categorized by the strategy of adaptability (phenotype) and
predictable outcomes allowing us to mathematically model evolution of species
populations with the given resources of an ecosystem [32]. Adaptations of these
mathematical methods have been used to determine the evolutionary potential of cancer
cells [10, 33]. These mathematical models utilize two broad control mechanisms of
multicellular organisms, which are tissue development regulators and substrate
availability [10, 33, 34]. The former consists of complex growth control mechanisms such
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as: cell-cell and cell-ECM (extracellular matrix) interactions, as well as, response to
soluble growth factors [35]. Glucose is the universal substrate in catabolic metabolic
reactions; thus tissue uptake capacity and basal metabolic uptake can be calculated
based on extant literature [10, 33].

Mathematical analysis of normal epithelial tissue dynamics reveals that
populations of normal cells have decreased fitness upon reaching tissue equilibrium [10].
Furthermore, evolutionary models show that loss of fitness is independent of growth
strategy (phenotype), which means that tissue stability is due to cooperation of coexisting non-competing populations, if more than one population with different survival
strategy were to exist within the same tissue [10, 33]. Therefore, each individual cell in
epithelial tissue gives away its individual growth potential for normal tissue development
and the overall good of the whole organism. This also implies that initial oncogenic
mutations will not cause cancer alone, but will rather be fixed into the tissue landscape.
Subsequent evolution of cancer is elicited by environmental factors such as
inflammation, which will cause clonal expansion of pre-cancerous tissue-fixed cells
giving room for acquisition of somatic mutations to further enhance fitness of mutant
cells causing a relaxation in growth regulation trough contact inhibition by disrupting to
cell-cell or cell-basement membrane interactions [35]. Further adaptations promoting the
cancer phenotype are induced by micro-environmental changes such as hypoxia and/or
lack of nutrients since cell population growth leads to separation from blood vessels [36].
Thus, mathematical simulation models of cancer evolution are possible if the factors of
dynamic progression of cancer are provided through experimental observation [10, 33,
34]. Based on mathematical modeling and experimental observations the evolutionary
model of carcinogenesis has 3 defined stages of cancer: initiation, promotion, and
progression, figure 3.
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PDAC carcinogenesis fits an evolutionary model of cancer progression since its
genetic signature is well characterized (KRAS, CDKN2A, TP53, SMAD4), as well as,
characteristics of its TME (hypoxia, acidosis, high interstitial pressure) and survival
outcome (activation of Warburg effect metabolism, fibroblast activation, immune
evasion) [5, 36, 37]. Thus, in its formative stages PDAC is limited by tissue growth
constraints (extrinsic factors), but once the oncogenic phenotype arises further survival
is defined by cellular homeostasis and the metabolic adaptations required to sustain it. In
the following sections I will address how pancreatic epithelial cells become oncogenic to
develop PDAC.

Neoplastic evolution of PDAC

The evolution of malignant cell into PDAC requires several steps that have been
histologically characterized by observable pancreatic lesions, also known as pancreatic
intraepithelial neoplasms (PanINs). The normal pancreatic ductal epithelium houses lowcuboidal cells lining ducts in a single layer and nuclear atypia is not seen [38]. PanIN-1,
is characterized by increased mucin secretion, cell elongation, and observable papillary
architecture. PanIN-2, is characterized by nuclear abnormalities such as: nuclear
crowding, hyperchromatism, and enlarged nuclei, as well as, some loss of polarity [38].
Cells budding into the lumen, nuclear atypia, and increased mitosis
characterize PanIN stage 3 [38]. PDAC diagnosis follows PanIN-3, as it is characterized
by invasive growth and marked desmoplasia [38]. PDAC tumors show an increased
frequency of mutations in KRAS, CDKN2A, TP53, and SMAD4 with increasing PanIN
staging [14].

Substantial evidence in PanINs suggests PDAC occurs in a linear progression.
Mutant KRAS is expressed in 99% of PanIN-1 and its proportionality increases in high-
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grade pancreatic lesions [38]. This indicates fixation of oncogenic KRAS in normal
pancreatic epithelium and its selection in pancreatic lesions. Loss of p16INK4A is known to
occur most often during PanIN-2 and it shows increased loss in PanIN-3 [38]. Loss of
TP53 and SMAD4 is known to occur in PanIN-3 lesions and invasive PDAC [38]. The
accumulation of these classic features of the PDAC genetic landscape show a pattern of
progression that seems to require progressive fixation of these mutations as if these
alterations are requirements in evolution of somatic cell to PDAC, i.e.
KRASàCDKN2AàTP53àSMAD4. In the following sections, I will address more
specifically the stepwise progression of PDAC.

1. KRAS

KRAS is a member of the RAS family of small-protein GTPases, whose enzyme
function is to hydrolize GTP into GDP and acts as a signal transducer when active in the
GTP conformation, figure 4 [39, 40]. In normal cells KRAS is activated by extracellular
growth factors and consequent growth-factor receptor activation. Active KRAS is an
important molecule in a plethora of signal transduction pathways, figure 4 [39, 40]. For
this reason it is instrumental in cell to growth, proliferation, as well as, maturation of cells
to take on specialized functions (differentiation) [39, 40]. Wild-type KRAS is regulated by
guanine exchange factor proteins (GEFs) whose function is to turn off/on by exchanging
GDP for GTP [39, 40]. Therefore, KRAS function is regulated by growth factors, GEFs,
and GTP/GDP ratio. Most mutations in the KRAS gene are believed inhibit GTP
hydrolysis thereby becoming constitutively active [39, 40]. KRAS is located on the short
arm of chromosome 12, and it suffers mutations in codons G12, G13, and Q61 with the
most common amino acid substitutions being G12D, G12V, G13D, and Q61H [39, 40].
Oncogenic KRAS expression is nearly ubiquitous in PDAC carcinogenesis with ~99%
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expression in PanINs and 95% in tumors [38]. Oncogenic KRAS provides fitness to
malignant cells because it mediates uncontrolled proliferation.

Several studies have demonstrated that autocrine epithelial growth factor (EGF)
signaling occurs in low-grade PanINs due to overexpression of EGF-family ligand
receptors EGFR and ERBB2 [5, 40, 41]. Similarly, EGF signaling results in stimulation of
the phosphatidylinositol-3-kinase (PI3K) pathways [41]. Activated KRAS can itself
interact with and activate PI3K [40]. PI3K acts on downstream effectors AKT and mTOR
(PI3K/AKT/mTOR transduction signaling pathway) and activates metabolic pathways
that enhance the cellular rate of macromolecule biosynthesis by increasing membrane
expression of nutrient transporters and glycolysis genes [41]. More specifically, AKT
stimulates lipid synthesis, while mTOR regulates protein translation [41]. Hypothetically,
acute damage to pancreatic epithelium will lead to increase in EGFR in response to
injury and to promote tissue regeneration. However, if a cell bearing oncogenic KRAS
has been fixed into the pancreatic tissue, increased cell turn over caused by tissue
damage will stimulate both EGFR-dependent activation of PI3K/AKT/mTOR pathway
and oncogenic-KRAS. In this scenario the mutant cells may expand because of growth
factor independency. However, cell division is restrained by cell-cell, cell-basement
membrane interactions, and growth cycle checkpoint inhibition [17]. Maintenance of
oncogenic KRAS is central for continued uncontrolled growth and increased metabolic
rate in advanced disease.

2. CDKN2A

The second genomic alteration in the PDAC stepwise progression is the loss of
tumor suppressor CDKN2A, which encodes for genes p16INK4A and p19ARF because of a
shared locus on chromosome 9p [42]. These genes are differentially regulated because
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of different reading frames on their first exon [43]. Interestingly, the CDKN2A locus is
inactivated 90% of the time in PDAC and evidence from mouse models and human data
suggests mutations are targeted for p16INK4A [44]. However, larger alterations to
CDKN2A locus will result in loss of both p16INK4A and p16ARF in an event that can
contribute to PDAC through different mechanisms [43]. p16INK4A plays an important role
in cell cycle regulation by inhibiting cyclin-dependent kinases CDK2 and CDK4
(cyclinD/CDK2,4 complex), which phosphorylate retinoblastoma protein (pRB) causing
its disassociation from E2 Factor (E2F) thereby allowing it to begin transcription of
cylcinA and cyclinE [45]. These last two may interact with CDK2 (CyclinA, E/CDK2
complex) inducing passage through G1/S-checkpoint of cell cycle, figure 5 [45]. Loss of
CDKN2A gene is commonly seen in medium-grade pancreatic lesions, PanIN-2 [5, 38].
Therefore, this adaptation is likely to favor established oncogenic KRAS mutants by
allowing the biosynthetic machinery to make more DNA. Furthermore, induction of
CDKN2A increases during environmental stress to suppress mitogenic stimulation [45].
The KRAS-CDKN2A mutations promote DNA synthesis that leads to the genomic
instability seen in PanIN2, which may cause DNA sequence errors and/or shortening of
telomeres to occur forcing activation of TP53 gene to transcribe p53 DNA damage
response genes and cause senescence or apoptosis. Thus, the genetic alterations in
KRAS and CDKN2A/p16 are likely to cause extensive genomic alterations forcing
adaptation to suppress DNA damage response, anti-proliferative, and anti-senescence
mechanisms all of which may be regulated by p53.

3. TP53

The tumor protein 53 (TP53), or p53, is a transcription factor whose function is
stimulated in response to DNA damage or stress. p53 activation in normal cells leads to
growth arrest or apoptosis to maintain genome integrity; hence, its proclamation as
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guardian of the genome [46]. TP53 is somatically mutated, approximately, in 85% of all
PDACs, with nearly 66% of mutations targeting its DNA binding domain [38]. The role of
p53 in protecting genome integrity of pancreatic cells in preventing PDAC, as
demonstrated by familial PDAC that is induced by is loss of gene ataxia telangiectasia
mutation (ATM) whose function in cells is to relay stress signals to p53; loss of p53
signaling axis leads to high risk and induction of PDAC [47]. Dysfunctional p53 would not
conduct G1/S and G2/M checkpoints or respond to telomere shortening [46]. Thus,
absence of p53 response to genomic damage will result in uncontrolled proliferation.
Mutations in TP53 gene correlate with significant features of dysplasia in PanIN-3 [38].
Absence of p53 improves fitness of cells bearing oncogenic KRAS and CDKN2A, as the
removal of mitosis breaks will result in clonal expansion leading to loss of polarity
diminishing growth constraints due to cell-cell and cell-basal membrane interactions.
Furthermore, increased rate of mutations will likely select for a new genotype capable to
survive in emerging microenvironment stress factors. Figure 6 highlights the p53
response in normal cells.

4. SMAD4

SMAD4 function is lost in approximately 55% of PDACs and contributes to PDAC
progression due to inactivation of TGFβ-mediated growth inhibition, which blocks G1/S
cell cycle transition [38, 48]. Interestingly, the TGFβ pathway plays an inhibitory role in
PanIN-1 and PanIN-2, but supports progression to PDAC in PanIN-3 role possibly
because it promotes paracrine signaling leading to activation of pancreatic stellate cells
(PSCs) that cause tissue desmoplasia [49]. Indeed, loss of SMAD4 shows the
predisposition of PDAC to form a strong desmoplastic reaction because familial loss of
SMAD4 does not predispose to PDAC [50]. However, if familial SMAD4 mutation is
concomitant with PDAC, the cancer is more aggressive and highly fibrotic [50]. Deletion

14
of SMAD4 is a late event in PanIn3 progression to PDAC and is likely a progression
allele in PDAC. Nevertheless, loss of function of SMAD4 decreases ability to restrict
unrestricted proliferation and as a result it would lead to increase in fitness of PDAC
cells.

Features of Pancreatic Ductal Adenocarcinoma
Genetic expression analyses of PDAC progression in human samples suggests
progression of PanIN-1 to PDAC takes approximately 12 years [51]. The time between
PanIN lesions and PDAC is not well defined. However, experimental evidence suggests
a 3-step process clonal transformation, clonal expansion, and invasion. First ductal cells
require an oncogenic mutation (KRAS) (transformation), second the mutant cells need to
become the dominant phenotype in the tissue (clonal expansion), and lastly intrinsic
mechanisms of tumor suppression need be removed through loss of tumor suppressor
function (CDKN2A and TP53) (invasion). Movement of the transformed cell population
from the pancreatic ducts into the ductal lumen and developing a stroma characterized
by increased desmoplasia and further clonal expansion; these are the histological
features of PDAC [38]. Stochastic growth follows initial spread of malignant cells into the
pancreas, as the cancer population faces growth and environmental challenges [52].
Further progression of cancer is not immediate as evidenced in genetic expression
analyses suggesting progression form early PDAC to metastatic PDAC takes nearly 7
years, possibly because of tissue instability and immune response. During this time,
PDAC cells generate a dynamic and complex TME characterized by infiltration of various
cell types, extensive extracellular matrix (ECM), as well as, restricted nutrient and
oxygen availability [37]. Thus, the TME of the PDAC tumor imposes potent selection
forces to shape ongoing adaptation and promote clonal expansion of initial populating
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cells, which in turn will increase cellular heterogeneity of cancer cell population. Fitness
of cancer cells must be enhanced trough genetic, epigenetic and phenotypic alterations
in order to outcompete the host.

The time elapsed between gain of metastatic potential and the time of death is
predicted to be nearly 3 years [51]. PDAC diagnoses are assigned four stages: stage 0
(non-invasive), stage 1 (invasion throughout pancreas), stage 2 (lymphatic invasion),
stage 3 (invasion to nerves and blood vessels), and stage 4 (metastatic) [3]. Alarmingly,
nearly 80% of all cases are found to be invasive with 50% of these bearing metastatic
sites [2, 3]. It has been observed that metastasis is an early event in PDAC [53]; thus,
tumors do not follow this staged linear progression to metastasize. It is more likely that a
random wave of alterations improve fitness of cells in primary site giving rise to cells with
metastatic potential. Indeed, genetic expression analyses indicate tumor heterogeneity
derives autonomous and non-autonomous cell population. In terms of tumor evolution
this means that cancer cells in the primary tumor site must become fixated to the tumor
tissue landscape. Once a landscape threshold is reached, cancer cells will be obligated
to undergo further selection to gain autonomy from primary tumor constraints the result
is gaining the ability to metastasize. Similarly, the same selection process is likely to
induce formation of cancer stem cells, which is another survival strategy. This notion is
supported through several lines of evidence such as the fact that 99% of metastatic
attempts fail as cells cannot survive more than 24 hours [54]. There is also no genetic
signature for metastases, but metastasis is favored by acquisition of pre-malignant
mutations (KRAS, CDKN2A, TP53, and SMAD4) [55]. Lastly, mathematical models also
agree that adaptation to microenvironment before metastasis requires 5-10 years [51].
Figure 7 highlights the progression of PDAC.
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PDAC cancer cells exponentially increase substrate uptake, as demonstrated by
[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging of human
tumors, which shows significantly increased glucose uptake of tumors compared to
normal adjacent tissue [36, 56]. The metabolic shift to increase aerobic glycolysis and
limitation of mitochondrial oxidative phosphorylation, also known as the Warburg effect,
is a universal feature of solid tumors since increase in glucose uptake is up to 1000
times more than normal cells [34, 36, 56]. Thus, FDG-PET scans are conducted to
diagnose PDAC and for evaluation of therapy response of primary site and metastases.
This behavior of cancer cells is logical because cells need biomass to proliferate to
achieve this metabolic output is maximized [36]. A caveat of increased metabolism is
excess production of metabolic acids. Interestingly, cancer cells exhibit a unique pH
gradient in which the internal pH (pHi) is alkaline raging from pH 7.3-7.6 and an acidic
extracellular pH ranging from pH 6.5-7.0. Experimental evidence shows that an alkaline
pHi enhances metabolic rate, but decreased in pHi limits proliferation and survival of
cancer cells [57]. In evolutionary terms, this means that survival/fixation of cancer cells in
primary tumor landscape and further progression exclusively depends on pH regulation.
In the following sections I will address the emergence of altered metabolism in PDAC
and evolution to dysregulated pH dynamics because of Warburg effect metabolism.

Desmoplasia a Hallmark of PDAC

The response to heal tissue damage in the pancreas is particularly strong, as
evidenced through histological observations in the pancreas of patients with chronic
pancreatitis [38, 58]. Activation of fibroblasts leads to deposition of fibers during wound
healing response; this is an evolutionarily conserved response to support the
multicellular state of higher organisms [59]. Regulation of fibroblasts is coordinated
largely through the transforming growth factor beta, TGFβ, signaling [59]. Other features
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of wound healing processes include immune suppression, remodeling of the ECM, and
increase of epithelial growth factors in order to recover cells lost through injury [60]. The
role of increased stromal fibrosis in PDAC carcinogenesis is unchallenged as it
enhances immune suppression, drug resistance, and promotes hypoxia—a feature
associated with emergence of metastatic cells [61, 62]. Tumor cells activate quiescent
pancreatic stellate cells (PSCs) through paracrine signaling from secretion of platelet
derived growth factor (PDGF), TGFβ, and sonic hedgehog [61]. Upon activation,
quiescent PSCs differentiate into alpha-smooth muscle actin myofibroblasts (αSMAs)
allowing for further activation through autocrine signaling by PDGF, fibroblast growth
factor (FGF), and TGFβ [61]. Unlike normal tissue where fibroblast activation is inhibited
upon wound healing, in cancer PSCs are constitutively activated through cancer cells
paracrine signaling. Thereby resulting in continuous deposition of fibers in the tumor
stroma.

Extensive evidence shows that PDAC cannot develop without activation of the
desmoplastic stroma [61]. As evidenced by pharmacological inhibition of PSC activation
in mice resulting in stromal collapse, development of smaller tumors, and overall more
effective response to therapy [37]. Similar results were produced through inhibition of
sonic hedgehog (SHH) signaling and upon depletion of enzymes responsible for
hyaluronic acid (HA) deposition—a major component of PDAC tumor stroma [37, 61].
Contrastingly, it has also been demonstrated that depletion of carcinoma-associated
fibroblasts and fibrosis through deletion of αSMA myofibroblasts themselves or SHH
induces immunosuppression and accelerates PDAC progression and reduces survival
[37]. These observations suggest that distinct components of the PSCs secretome have
different properties in promoting or restraining tumor growth. The same logic can be
applied for other tumor-stroma resident cells as well, such as macrophages whose
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polarization as M1 leads to anti-tumorigenic response and M2 polarization leads to a
pro-tumorigenic response [63]. Interestingly, these opposite properties may have a
spatially and timely effects on selection of cancer cell populations, as this would lead to
loss of a clonal population and replacement by a fitter clone. These waves of growth are
likely to contribute to stochastic evolution of PDAC tumor.

The PDAC stroma ECM is rich in HA, fibrillar collagens, and osteonectinn;
collectively, these molecules make the dense stroma that functions as a physical barrier
shielding the tumor [61]. Consequentially, increased fibrosis results in poor diffusion of
oxygen to cancer cells resulting in wide spread hypoxia throughout the tumor [37].
Furthermore, HA is a negatively charged glycosaminoglycan that binds large amounts of
water molecules leading to increased interstitial fluid pressure (IFP) [64]. Pathologic IFP
occurs because of increased HA in stroma leading to swelling and collapse of the tissue
vasculature thereby limiting oxygen diffusion [65]. It may seem detrimental but restriction
of metabolic substrates oxygen and glucose would be a strong selection force for
survival pathways such as autophagy, pinocytosis, endocytosis, as well as, metabolic
reprogramming to compensate for glucose such as glutamine uptake [61, 62, 64-66].
Glucose diffuses radially 280µm away from blood vessels where as blood only diffuse
200 µm; therefore, hypoxia posses a powerful selective force for survival in highly fibrotic
tissue [10, 36]. Hypoxic TME is a classic feature of PDAC tumors, cells adapt to hypoxia
through metabolic reprogramming to make better use of resources and continue
proliferating [36]. The classical response to hypoxia is activation of hypoxia inducible
factor HIF that functions as a master regulator of anaerobic metabolism and neoangiogenesis [62]. In addition to HIF response, oncogenic KRAS, other oncogenic
mutations, as well as growth factors can also up-regulate glucose metabolism thereby
promoting fitness in hypoxic microenvironment [39].
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One of the hallmarks of cancer is the ability of cancer cells to kick start formation
of new vasculature, neoangiogenesis [67]. Indeed, the cancer cells themselves can
secrete angiogenic factors through inherent mechanisms or environmental mechanisms
via HIF response [67]. Furthermore, factors secreted by PSCs such as osteonectin are
known to induce neangiogenesis [68]. This means that the fibrotic stroma creates
dynamic microvasculature leading to periodic cycles of moderate to deep hypoxia, which
will favor selection of Warburg effect metabolism. Metabolic reprogramming is
reminiscent of ecological studies that have shown success of invasive species through
better utilization of limited resources to grow their population. A more elaborate depiction
of metabolic reprograming and its role in cancer cell fitness will be provided in the
upcoming sections.

The Immune System in PDAC

The immune system is one of the marvels of evolution that contributes to the
overall homeostasis of multicellular organisms by eliminating foreign invaders through
the combined action of specified cells, tissues, and organs. Thus, the immune system is
critical in cancer prevention as it can recognize malignant cells as foreign entities and
eliminate them. Evasion of immune response is critical for emergence of initial somatic
mutations and metastasis, as cells need to avoid detection and continue their oncogenic
processes [69]. Several lines of evidence suggest that the microenvironment of early
pancreatic duct lesions is immunosuppressed [70]. Therefore, the immune system
imparts selective pressure for mutant cells in early neoplastic lesions to develop
mechanisms of immune evasion and produce a phenotype that can evade the immune
response, as well as, other growth constraints. Where as in PDAC tumors, there is
evidence the TME leads to T-cell suppression through accumulation of CD4 positive
regulatory T-cells (Treg), M2 tumor-associated macrophages, and myeloid-derived
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suppressor cells [70]. Accumulation of T-cells in the TME demonstrates that endogenous
T-cells are functional, but upon arriving to the TME they become suppressed.
Mechanisms of T-cell exhaustion include expression of inhibitory effectors (PD1, LAG3,
TIM3), high-antigen tumor load, and immunosuppressive TME due to hypoxia or
acidosis, as well as, limited nutrient access [71].

PDAC Metastasis
Metastasis is managed clinically as late event in carcinogenesis, but from an
evolutionary standpoint it is a reflection of clonal competition and fitness levels in the
primary site. However, local tissue invasion itself is not a rate-limiting step in formation of
metastases; this is because clonal expansion is a random process meaning that each
replication cycle can yield metastatic cells, but PDAC progression seem to be a
stochastic process and TME and cell population may drive metastatic selection of clones
[72]. Furthermore, more than 99% of cells that enter the circulation do not survive in
blood beyond 24 hours [52]. These observations suggest metastasis will be more likely
with increasing tumor cell population growth; moreover, dissemination occurs from the
earliest stages of pancreatic carcinogenesis meaning that PDAC tumors undergo rapid
growth early in PDAC carcinogenesis. However, early carcinogenesis is an ambiguous
term as PDAC goes undetected for years before diagnosis and thus its timely
progression is not well described. Nevertheless, metastasis can occur on first replication
cycle, but statistically it will be more favored upon establishment of primary tumor.
Interestingly, no metastasis-specific genes have been found in pancreatic cancer;
instead, a substantial proportion of metastatic efficiency is determined by the genetic
alterations that arise during the clonal expansion phase (KRAS, CDKN2A, TP53 and
SMAD4) [51, 52]. Thus, the genetic features of the parental clone play an instrumental
role in determining the extent to which the clone will successfully adapt and survive in
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foreign microenvironments. Evidence to support the notion that metastasis develops
from evolution of cancer cells in the primary site comes from genomic studies of patients
with metastatic lesions showing that the metastatic cell population arises from cells in
the primary tumor site identified by their unique set of passenger mutations and
structural rearrangements, which are genetic markers of the life history of that lineage
[73]. Additionally, mathematical models factoring immune response, phenotypes, and
stochastic evolution predict metastatic success least 5–10 years following development
of the parental clone [51].

These observations highlight the significance of timely adaptation of PDAC cells
to the TME to achieve development of metastatic lesions. The complementary features
for induction of metastasis of PDAC cells acquired in TME of the primary site that
promote metastasis to the liver, lungs or peritoneum are still undiscovered. Evidence of
selection for metastatic phenotype is shown in an interesting recent study of orthotopic
PDAC mouse models where it was shown that organ-specific metastases are enhanced
upon multi-clonal implantation [74]. Perhaps this is an artifact of competition and use of
resources since PDAC cells lines have been shown to belong into three metabolic
subtypes that are associated with glycolysis, lipogenesis, and redox pathways [75]. This
implies that metabolism of PDAC cells plays a critical role in the phenotype of PDAC
cells and whether they are primary site cells, metastatic, or therapy resistant. In the
following sections the significance of metabolism in carcinogenesis with specific focus on
PDAC.

Cellular Metabolism
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One of the hallmarks of cancer is up regulated metabolism this occurs because
cancer cells are unresponsive to tissue-mediated growth inhibition, as well as, loss of
intrinsic growth regulators (oncogenic mutations); thus cancer cells begin to proliferate
uncontrollably. In the following section the role metabolism plays in cellular energetics
and growth will be addressed.

Metabolism refers to the biochemical processes within an organism through
which energy and biomass are produced to sustain homeostasis and growth of an
organism. Inside of a cell, nutrients are broken down and linked in a series of enzymecatalyzed chemical reactions also known as metabolic pathways. The reactants,
products, and intermediates of these reactions are also referred to as metabolites. In a
metabolic pathway the product of a reaction is the substrate for the next. Critical for
metabolic enzyme-driven reactions are co-factors derived from vitamins or dietary
minerals. There are two types of metabolic pathways: catabolic and anabolic. The
function of the former is to break down metabolites, which release energy that is
harnessed by the cell while the latter utilizes energy for biosynthesis of macromolecules.
These two processes compliment each other because catabolism produces energy and
anabolism consumes it during biosynthetic reactions. Figure 8, highlights catabolicanabolic relationship.

Glycolysis, breakdown of glucose, is a ubiquitous metabolic pathway in all living
cells. The glycolytic pathway takes place in the cytoplasm producing 2 pyruvate
molecules and 4 adenosine triphosphate (ATP) molecules through substrate level
phosphorylation of ADP (ADPàATP). ATP’s phosphate bonds hold potential energy,
which generate free energy used by the cell when they are broken—hence ATP is the
energy currency of the cell. However, 2 reactions in glycolysis require modification
through phosphorylation, hexokinase [glucoseàglucose-6-phosphate] and
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phosphofructokinase [fructose-6-phosphateàfructose-1,6-bisphosphate], because of
this expenditure of energy glycolysis only produces a net of 2 ATP molecules for the cell.

Approximately, 2.3 billion years ago the atmospheric levels of O2 increased to
35%, today they are 21%, this caused a branching point in metabolism [76]. Glycolytic
process uncoupled from oxygen became known as anaerobic metabolism or aerobic
metabolism when coupled to oxygen. In anaerobic metabolism glucose-derived pyruvate
is converted to lactic acid through a process called lactic acid fermentation. This process
also reduces glycolysis co-factor nicotinamide adenine dinucleotide, NAD+ àNADH,
which can then be recycled for sustained glycolysis. In aerobic glycolysis, glucosederived pyruvate is delivered to the mitochondrion—the cell’s ‘engine room,’ where it is
converted into acetyl-coA via pyruvate dehydrogenase complex. Acetyl-coA is oxidized
in a series of reactions collectively known as the tri-carboxylic acid (TCA) cycle using cofactors nicotinamide adenine dinucleotide (NAD+) and flavin adenine dinucleotide
(FAD+), which are reduced in the process—NADH, FADH2. Energy is generated through
the electron transport chain (ETC), a system composed by a series of protein-complexes
installed in the inner membrane of the mitochondria. The ETC conducts a series of
reduction/oxidation reactions moving electrons from NADH and FADH2 to O2, which
picks up protons and converts to water. Complex I,II, III and IV of ETC move protons
produced through oxidation reactions in TCA cycle, into the inter-membrane of the
mitochondria generating an electrochemical gradient. While, Complex V of the ETC recycles protons back into the inner membrane of ETC using the potential energy
movement of protons down their concentration gradient for ADPàATP phosphorylation.
This whole process is possible because of oxygen is the final electron acceptor—hence
the term oxidative phosphorylation. Reference [77].

Metabolic Control
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Aerobic metabolism generates more energy allowing approximately 1000 more
reactions to take place compared to anaerobic metabolism, which led to generation of
new metabolites enabling cellular biosynthetic potential [76]. For example, the oxidative
decarboxylation of pyruvate to acetyl-CoA commits the carbon atoms of glucose to two
principal fates: oxidation to CO2 by the citric acid cycle or incorporation into lipid via fatty
acid synthesis. In eukaryotic cells the major metabolic control is through
compartmentalization with glycolysis occurring in the cytosol and oxidative metabolism in
the mitochondria. Enzymes are potential sites for regulation of metabolic pathways,
more specifically enzymes catalyzing irreversible reactions. The significance of
metabolic regulation is crucial for maintaining basal metabolic rates in normal cells.

In glycolysis, the reactions catalyzed by hexokinase, phosphofructokinase, and
pyruvate kinase are irreversible; thus, each of them serves as a control site with their
respective function regulated by the reversible binding of allosteric effectors or by
covalent modification. Allosteric regulation is mediated by a feedback loop of reaction
and pathway products. In addition, the expression of these enzymes is tightly regulated
by transcription factors in response to metabolic needs. The oxidative decarboxylation of
pyruvate to acetyl-CoA is a critical branch point in metabolism. For this reason the
activity of the pyruvate dehydrogenase complex is controlled by several means such as
negative feedback of reaction products, as well as, covalent modification through
Phosphorylation of the pyruvate dehydrogenase complex by pyruvate dehydrogenase
kinase; while deactivation is reversed by pyruvate dehydrogenase phosphatase.
Increasing the NADH/NAD+, acetyl CoA/CoA, or ATP/ADP ratio promotes
phosphorylation and, hence, deactivation of the complex. For this reason the pyruvate
dehydrogenase complex is switched off when the energy level is high and biosynthetic
metabolites are abundant. The rate of the citric acid cycle is precisely adjusted to meet
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an animal cell's needs for ATP. The primary control points are isocitrate dehydrogenase
and α-ketoglutarate dehydrogenase enzymes through allosteric inhibition of pathway
products. Thus, regulation of TCA cycle is primarily due to NADH/NAD+ or ATP/ADP
ratio. Reference [77].

Metabolic regulation a balance for growth and survival

Consider the fact that the biomass of microbes nearly doubles that of higher
multicellular organisms. Needless to say, the number of microbial species far
outnumbers that of multicellular organisms. This is because, microbes have been
selected to grow as fast as possible when nutrients are available. Physiologically, this
means that they need to re-wire their metabolic biochemistry from ‘survival mode’ to
‘growth/replication mode’ in order to achieve this there must be a switch from basal
metabolic rate to a metabolic rate competent to generate biomass required for
exponential growth. Upon malignant transformation, cancer cells gain fitness and adopt
a metabolic phenotype that is reminiscent of microbial exponential growth in order to
produce an exact copy of itself.

As previously described, normal cell function is maintained through the catabolic
metabolism of glucose to generate free energy through oxidative phosphorylation. To
sustain homeostasis and remain functional normal cells also need to undergo anabolic
metabolic processes, which requires harnessing of biomass from nutrients to synthesize
macromolecules as needed [56, 78]. ATP may be used for activation of some reactions,
but anabolic processes need biomass and cofactors. Thus, it is illogical that all carbons
would be maximized for energy production. For example, the synthesis of palmitate, the
most common saturated fatty acid found in plasma membrane of animals, requires 7
molecules of ATP, 8 molecules of acetyl-CoA, and 28 electrons from oxidized NADP+,
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NADPHà NADP+. Similarly, the synthesis of amino acids and nucleotides requires more
biomass and NADPH than ATP molecules. Oxidative metabolism of glucose yields a
maximum of 36 ATP molecules and 2 NADPH molecules. NADPH will only be produced
if glycolysis is branched into the oxidative arm of the pentose phosphate pathway (PPP).
Thus, the amount of ATP produced through oxidative metabolism of glucose far exceeds
its need. In the example of palmitate, a glucose molecule may provide 6 carbons while
16 carbons are required for the fatty acyl chain. Similarly, a single glucose molecule can
only reduce 2 NADP+ units; therefore, 7 glucose molecules are needed to make
palmitate. These examples illustrate the fact that glucose cannot be committed to ATP
synthesis entirely as it is counter productive for anabolic processes. Reference [56, 79]

In addition to glucose, the amino acid glutamine is essential for bioenergetics,
redox, and biosynthetic reactions. This is because glutamine is the most abundant
amino acid in blood and muscle, for this reason, glutamine has become an essential
metabolite for cell functions. For example, glutamine can be broken down through
glutaminolysis to derive acetyl-CoA and generate energy via oxidative phosphorylation.
Glutamine can also undergo anabolic pathways, annaplerosis, to synthesize
macromolecule such as, non-essential amino acids (NEAAs), purines, pyrimidines, and
fatty acids. Furthermore, glutamine is used to make antioxidant molecule glutathione.
For this reason many cells shift their metabolism to be more dependent on glutamine for
their survival, growth, and proliferation. Cells that become glutamine dependent show
that up to 90% of their oxaloacetate is derived from glutamine. Glutaminolysis is a
process exclusive to the mitochondria, it begins with uptake of glutamine and its
conversion to glutamate by glutaminase enzymes (GLS1/GLS2), and glutamate is then
converted into α-ketoglutarate via two diverging pathways. The canonical anaplerotic
pathway occurs through action of glutamate dehydrogenase (GLUD). The second
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pathway is via the non-canonical anaplerotic pathway is conducted by glutamate
transaminase enzymes (GOT). Metabolic flux through the canonical pathway generates
ammonia and NADH from decarboxylation of α-ketoglutarate in the TCA cycle. An
interesting fact is that ammonia is an inducer of autophagy, a system through which
glutamine is provided for metabolism. Contrastingly, the non-canonical pathway
generates NEAAs instead of ammonia, including aspartate, alanine, and phosphoserine.
Glutamine-derived OAA can condense with acetyl-CoA to make citrate, which is a
substrate for ATP-citrate lyase (ACLY) for de novo lipogenesis via fatty-acid synthase
(FASN). Glutamine-derived fatty acids can also be made through cytosolic isocitrate
dehydrogenase (IDH1) in a caboxylation reaction. Similarly, glutamine-derived
metabolites can be shuttled out of the mitochondria through shuttling mechanisms. For
example, glutamine-derived aspartate can take part on the malate-aspartate shuttle and
produce NADPH via malic enzyme 1 (ME1) or NADH through ME2 in the mitochondria
compartment. Aspartate can also be converted to asparagine and participate in
nucleotide synthesis pathways. Glutamine has been shown to play a critical role in cell
metabolism and cells that rely solely on glutamine die upon depletion unless they
undergo adaptation to glutamine depravation. Indeed, cells that are glutamine
independent have increased expression of pyruvate carboxylase (PC), which converts
pyruvate to OAA that is used to maintain TCA cycle if PDH is inhibited. Thus, when cells
are stimulated to undergo growth the biosynthetic components: energy, biomass, and
co-factors of reactions can be generated from glucose, amino acids (glutamine), and
lipids (fatty acids). Reference [80]. Figure 9 highlights the canonical metabolic pathways.
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Cancer Cell Metabolism
A hallmark of cancer is the metabolic shift characterized by a marked increase in
glucose uptake and subsequent lactic acid fermentation, compared to normal cells, in
the presence of oxygen. German scientist Otto Warburg, hence the name Warburg
effect discovered this phenomenon a century ago [81]. At the time, Warburg’s
observation contradicted the Pasteur effect dogma, which described a metabolic shift
between lactic acid fermentation and oxidative metabolism depending on oxygen
availability. For nearly half a century, it was widely believed that cancer cells lacked
functional mitochondria. However, the discovery of oncogenes and tumor suppressors,
as well as, the improvement in genomic studies removed interest from cancer
metabolism studies until the beginning of the 21st century. In the previous section, I have
explained metabolic regulation and the theoretical role of anabolic metabolism upon
growth stimulation. Cancer is characterized by uncontrolled cellular growth which,
means that to produce viable cells during mitosis, a cancer cell must double its cellular
content, which implies the synthesis of billions of nucleotides, lipids, and amino acids
[56, 78]. Thus, cancer cells hijack cellular metabolism to maximize biosynthetic potential
to produce macromolecules, energy, and maintain redox homeostasis. To achieve this
functions and increase proliferation cancer cells exponentially increase glucose and
glutamine uptake. Indeed, C13 glucose/glutamine uptake in glioblastoma shows that up
to 90% of glucose and 60% of glutamine is committed to lactate synthesis [82]. The high
rate of conversion of glucose and glutamine into lactate seen in cancer cells is mediated
by lactate dehydrogenase A (LDHA). Inhibition of LDHA has shown to diminish growth of
cancer cells possibly as it will limit secretion of excess carbon in a process recycles
NADH, which is needed for continuous use glycolysis and TCA cycle metabolism [83].
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Similarly, increased glucose/glutamine uptake allows cells to generate NADPH
necessary for anabolic pathways and redox homeostasis.

Cells in a multicellular organism do not experience shortage or resources; thus,
there is no selective pressure for optimizing metabolism for maximum ATP yield.
However, selection for optimization of anabolic metabolic response does take place in
effector cells of the immune system. This is because upon damaging injuries the body
has to heal quickly in order to survive. Thus, it’s only logical that a fast responding
immune system evolved. Cells capable of utilizing glucose and glutamine more
effectively will proliferate faster. In the next section, I will elaborate on the development
of PDAC metabolism.

Hypoxia: Orchestrator of PDAC glycolytic metabolism

Increased expression of key glycolysis enzymes in PDAC leads to a robust
increase in metabolic activity and Warburg effect metabolic phenotype. These enzymes
include, hexokinase 2 (HK2), phosphoglycerokinase 1 (PGK1), pyruvate dehydrogenase
kinase isozyme 1 (PDK1), lactate dehydrogenase A (LDHA), enolase 2 (ENO2), and
pyruvate kinase muscle 1 and 2 (PKM1,2), as well as, increase espression of membrane
transporters such as glucose transporter 1 (GLUT1) and monocarboxylate transporters 1
and 4 (MCT1,4) [66]. This metabolic shift is likely due in large part to stabilization of HIF
complex because of hypoxia induced by strong desmoplastic reaction. HIF is regulated
by oxygen perfusion therefore; when oxygen is depleted the HIF1α subunit of the
complex is stabilized allowing for its interaction with HIF1β and subsequently recruitment
to the nucleus as a complex to begin transcription of HIF response elements (HRE) [62,
84]. The HIF response is a ubiquitous response for oxygen depletion and survival is
promoted by increase in glycolysis and induction of neo angiogenesis [62, 84]. HIF1α
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has an oxygen dependent degradation domain that is hydroxylated by propyl
hydrolylases (PHDs). Hydroxylation of HIF1α allows for recognition by the von-Hippel
Lindau binding protein, which is an E3 ubiquitin ligase that signals for HIF1α degradation
[62, 84]. Because activation of HIF complex is a ubiquitous response mutations in the
pathway are uncommon; however, the renal-cell carcinoma cell line RCC4 has shown
mutations to VHL and as a result there is increased expression of HIF1α [85]. The role of
HIF response in PDAC is undisputed and nearly 90% of tumors have increased
expression of HIF1α. As a result PDAC cancers have increased glycolysis followed by
high rate of lactate secretion. Figure 10 highlights HIF1α stability and HIF complex
metabolic response.

However, it is not conclusive to say that stabilization of HIF1α induced by the
hypoxic TME is the cause of Warburg effect in PDAC. For example, hyperglycemia
occurs as a result of diabetes type II, which predisposes for PDAC and it’s often a
symptom of PDAC as well; replication of hyperglycemia conditions in vitro indicates an
increase in HIF1α expression in normal oxygen conditions [86, 87]. Stabilization of
HIF1α has also been demonstrated to occur upon growth factor signaling, PI3K, heatshock protein 90 (HSP90), and cyclooxygenase-2 activity (COX2) [88-91]. Other factors
increasing HIF1α protein expression include ROS stress, nutrient depravation, growth
factor signaling, metabolic disturbances such as increases succinate, as well as, proteinprotein interactions resulting in enhanced stability, acetylation, or phosphorylation [84,
92]. For example, a study from our lab showed that the cytoplasmic terminal of MUC1
associates with HIF1α promoting its stability and subsequent engagement in
transcription of glycolytic genes [93, 94]. However, it is very likely that constitutive
stimulation of HIF in PDAC is because of cyclic hypoxia throughout premalignant lesions
and during establishment of primary tumor because of dynamic fibrotic stroma [95]. This
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is consistent with the somatic evolution of PDAC to adopt Warburg effect metabolism
independent of HIF, as it occurs in vitro. Thus, hypoxia response is critical because cells
need to adopt this metabolic behavior to survive inconsistent oxygen perfusion due to
growing stroma; where as normal ductal cells cannot survive prolonged absence of
appropriate oxygen levels because hypoxic metabolic response will lead to tissue
damage and turnover due to disruption of pH dynamics in exocrine pancreas [29].
Furthermore, PDAC cell lines with HIF1α depletion still exhibit increased glycolytic
metabolism clearly indicating that the metabolic phenotype is maintained through
oncogenic transformation, as it would promote fitness over normal cells [96].

KRAS Orchestrator of PDAC glycolytic metabolism

Oncogenic KRAS occurs almost ubiquitously in PDAC found in low-grade PanINs
and with magnified expression in PDAC cells [38]. Its constitutive activity triggers several
signal transduction cascades such as PI3K-AKT-mTOR, RAF-MEK1/2-ERK1/2 (MAPK),
Ral-GEF, and Rho-Rac, which eventually relays signal to activate transcription
mediators in the nucleus including c-MYC, NFκB, E2F, HIF1a, AP-1, and C-jun,
Introduction Figure 4 [97, 98]. In this way, oncogenic KRAS effectively regulates a
plethora of cellular activities such as cell growth, survival, migration, and metabolism.
For these reasons oncogenic KRAS is essential for PDAC carcinogenesis. However, its
expression alone is not sufficient to induce PDAC. As demonstrated in mouse models
bearing only oncogenic KRAS that gives proliferation to cells in PanIN, but does not
progress to PDAC likely due to tissue growth constraints [99]. Several lines of evidence
suggest KRAS selects for Warburg effect phenotype. For example, transfection of
oncogenic KRAS into human pancreatic ductal cells causes a moderate metabolic
increase compared to PDAC cells; similarly, oncogenic KRAS (G12V) in embryonic
kidney cells is known to induce up regulation of glycolysis at the cost of mitochondrial
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dysfunction [100]. These examples also allude to the somatic evolution of PDAC to
adopt Warburg effect metabolism.

Oncogenic KRAS takes on metabolism through several effector pathways of
which the most prominent are the PI3K-Akt and MAPK pathways [98, 101]. The PI3-Akt
signaling pathway increases the transcription and translation of GLUT1, increase activity
of phosphofructo kinase (PFK), localization of HK2 to the mitochondria thereby
increasing rate of the reaction of glucoseàglucose-6-phosphate, and stabilization of
HIF1α [102]. While the activation of MAPK pathway increases transcription rate of HIF1α
[103]. Increased expression of HIF1α through RAS activity has been demonstrated in
other RAS driven cancers through inhibition of PI3K and ERK [102-104]. Similarly, wildtype RAS molecules overexpressed in in a variety of cancer types can be targeted by
inhibition of farnesyl transferase, which anchors RAS molecules to the plasma
membrane, resulting in metabolic stress due to reduced HIF1α expression [105-107].

1. KRAS driven glutamine addiction

As previously stated, glutamine is the most abundant metabolite in blood and,
along with glucose, it’s the major substrate for metabolic reactions in PDAC. Glutamine
in PDAC is preferentially metabolized via the non-canonical anapleurotic pathway
because of oncogenic KRAS expression. Indeed, a study by Son et al. found that KRAS
plays a direct role in glutamine metabolism by increasing expression of GOT1 and
reducing GLUD1 expression. In this way, oncogenic KRAS guides metabolic flux through
the non-canonical pathway. These findings show that PDAC up regulates non-canonical
glutamine metabolism in order to increase NADPH levels in order to maintain noncytotoxic ROS levels. Furthermore, this observation makes up for PDAC preference for
non-oxidative PPP by providing the NADPH that otherwise would be generated through
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oxidative PPP. Reference: [108]. Figure 11 highlights KRAS driven non-canonical
anaplerotic glutamine metabolic pathway.

2. KRAS re-directs glucose to PPP

The Pentose phosphate pathway (PPP) is a biphasic, oxidative and nonoxidative, cytosolic process that utilizes glucose, as the initial metabolite, and glycolytic
enzymes to generate initial metabolic molecules. However, unlike glycolysis PPP is an
anabolic process that produces 5 carbon sugars. The oxidative branch of PPP takes
glcose-6-phosphate from hexokinase reaction as its initial metabolite, which is then
converted to 6-phosphogluconolactone via glucose-6-phosphate dehydrogenase (G6PD)
[glcose-6-phosphà6-phosphogluconolactone]. This irreversible reaction commits
glucose to oxidative PPP and reduces 2 NADPà2 NADPH. Subsequently the reaction
6-phosphogluconolactoneà6-phosphogluconate takes place via hydrolase
gluconolactonase. The last step in oxidative PPP is the decarboxylation reaction of the
6-carbon molecule via 6-phosphogluconate that reduces 2 NADPà2 NADPH [6phosphogluconateàRibulose-5-phosphate]. Production of NADPH through oxidative
PPP is essential for suppression of oxidants using glutathione. This is because
glutathione reductase (GR) oxidizes NDPH and reduces glutathione
(GSSG+NADPHàGSH+NADP+), which is then oxidized by glutathione peroxidase
(GPX) moving the electrons to hydrogen peroxide converting it to water [GSH +
H2O2àGSSG + 2H2O]. This is noteworthy because GR is highly expressed in PDAC, as
well as, high levels of NADPH indicating the significance of ROS homeostasis.
Reference: [109, 110].

The non-oxidative PPP uses the 5-carbon sugar to generate intermediates for
synthesis of nucleic acids and nucleotides. If there is a shift in metabolic demand for
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ATP, pentose sugars from non-oxidative PPP can be recycled as intermediates of
glycolysis, recycled as fructose-6-phosphate and glyceraldehyde-3-phosphate. Similarly,
glycolysis intermediates can be used for nucleotide synthesis. This is the case of PDAC
where oncogenic KRAS simulates glucose uptake and conveys glycolysis intermediates
for biosynthesis of nucleotides and nucleic acids. The exact mechanism is not well
understood; however, inhibition of MAPK and ablation of c-MYC results in decreased
metabolic flux to non-oxidative PPP. Oncogenic KRAS makes up for loss of NADPH
synthesis through oxidative PPP by induction of non-canonical glutamine metabolism,
which increases NADPH needed for ROS homeostasis. Reference: [96, 109]. Figure 11
highlights KRAS driven non-oxidative PPP pathway.

3. Oncogenic KRAS Redirects Glucose to HBP

The hexosamine biosynthetic pathway (HBP) links glucose metabolism and
glutamine metabolism through Glucosamine-fructose-6-phosphate aminotransferase
(GFPT) [fructose-6-phosphate+glutamineàglucosamine-6-phosphate]. This is the initial
precursor in HBP for synthesis of UDP-GlcNAc (uridine diphosphate nacetylglucosamine), which is used by O-GlcNAc-transferase (OGT) for protein O-GlcNAc
glycosylaton. Interestingly, PDAC have high levels of O-GlcNAc glycosylated proteins
because of up regulation of HBP pathway enzymes and OGT, as well as, low levels of
O-GlcNAcase (OGA), which catalyzes de-glycosylation. KRAS increases glucose and
glutamine uptake, as well as, the expression of HBP rate limiting enzyme GFPT.
Increased HBP activity has been linked with tumor invasion and metastasis. Reference:
[96, 111]

Post-translational modification of PFK1 via O-GlcNAc glycosylation has been
shown to inhibit its activity thereby fluxing G6P to oxidative PPP or HBP [112].
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Furthermore, O-GlcNAc glycosylation stabilizes important transcription factors such as
p53, c-MYC, and β-Catenin [113]. Increased metabolic flux through HBP promotes posttranslational and epigenetic alterations that promote carcinogenesis by increasing
aneuploidy, as well as, secretion of insulin, TGFβ, and FGF [113, 114]. Thereby,
promoting mutability and communication to other cancer cells and tumor stroma resident
cells such as PSCs. Interestingly, HBP also modulates tyrosine kinase receptor signaling
in PDAC shown by inhibition of OGT, which caused decrease in EGFR, ErbB2, ErbB3,
and IGFR [113, 114]. Logically, glucose starvation reduces metabolic flux to HBP
thereby decreasing protein glycosylation, but it must be highlighted that this leads to
apoptosis by unfolded-protein-response [115]. Thus, protein glycosylation is critical for
protein stability and function, which will be essential for PDAC cell proliferation.
Furthermore, protein glycosylation is likely to mediate cellular differentiation by
modulating cell-cell adhesion, responsiveness to GFs, immune system evasion, and
signal transduction, through mechanisms not yet known. Thereby, HBP metabolic flux
may play a critical role in neoplastic lesions. Figure 11 highlights KRAS driven HBP
pathway.

4. Role of KRAS in fatty acid metabolism

In lung adenocarcinoma, it has been demonstrated a direct role of KRAS in fatty
acid synthesis through activation of ERK2 pathway that increases FASN expression
[116]. However, in PDAC the exact mechanisms of FA metabolism are not fully
elucidated, but PDAC cell lines show increased expression of FAO and FASN. Studies
comparing growth kinetics of normal ductal cells versus PDAC cells showed that a high
lipid diet enhances PDAC cells more [117]. This indicates that PDAC cells can be
stimulated to uptake lipids and used them for energy and biomass generation i.e.
membrane backbone. These observations have been recapitulated using PDAC mouse
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models fed a high fat diet versus low fat diet [118]. The high fat diet a marked increase in
metabolic rate and energy production thanks to an increase in molecules that regulate
uptake and oxidation of FAs. Indeed, high fat diets are known to be factors increasing
risk of PDAC [119]. The role of FA and its regulating mechanisms in PDAC are not well
known. Interestingly, it has been found that omega-3 FAs cause cancer cell death while
omega-6 FAs correlate with incidence of cancer, including PDAC [119]. This may be
because omega-6 FAs increase obesity, which incidentally increases cancer risk.

Role of p53 in Metabolic Regulation

Tumor suppressor p53 has long been shown to play key role in response to
stress such as DNA damage, hypoxia, and oncogenic activation. Upon these events,
p53 stalls growth (senescence) and induces apoptosis if damage is irreversible. To
achieve these functions p53 must regulate the metabolic response to sustain cells viable
upon stress. To intervene in metabolism, p53 interjects at many points in both glycolysis
and oxidative phosphorylation and works to balance these metabolic pathways thereby
inhibiting Warburg effect and growth associated with growth and carcinogenesis [120].
Therefore, loss of function of p53 will result not just in induction of mutations due to
failing DNA damage response, but also loss of metabolic regulation furthering PDAC
growth.

p53 increases the expression of cytochrome C oxidase 2 (SCO2) a critical
mediator of oxidative phosphorylation, as well as, GLS2 influencing canonical glutamine
metabolism to sustain TCA cycle and oxidative metabolism [121, 122]. p53 modulates
glycolysis as well by increasing expression of transporters GLUT1,4, and TIGAR (TP53induced glycolysis and apoptosis regulator) whose metabolic role is through inhibition of
fructose-6-phosphate conversion to fructose-1,6-bisphosphate by increasing activity of
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frucosebisphosphotase 2, which carries out the reverse reaction [120, 123]. In this way,
p53 would redirect glycolysis intermediates to the oxidative PPP for production of
NADPH and nucleotides. This function is critical for survival of cells upon replication and
reactive oxygen (ROS) stress; p53 also reduces glycolysis by decreasing expression of
phosphoglycerate mutase (PGM) [120]. In this light, it is easier to contextualize why
deregulation of p53 is so critical for carcinogenesis. Furthermore, because of the
contrasting role of p53 in inducing glycolysis for ROS or DNA damage response and
induction of oxidative metabolism to suppress high glycolytic rate, the stability of p53 is
critical to maintain basal metabolism and overall homeostasis. In PDAC the TP53
mutation affects the p53 DNA binding domain thereby affecting transcription only the
genes with a p53 response element; while other protein-protein interactions would
remain thereby allowing formation transcription complexes where p53 is an activator of
transcription [123]. For example, it has been observed that cells with p53 mutations to its
DNA binding domain do not affect p53-related increased expression of glucose
transporters [124]. Similarly, mutant p53 in liver tumors is implicated in high expression
of HK2 thereby increasing the glycolytic rate of cancer cells [125]. Furthermore, the
difference between basal levels of p53 versus increased levels of p53 during severe or
sustained stress might allow for the transcription of different sets of genes and a different
metabolic response. Thus, in PDAC p53 transcription may still occur as cellular stress
will induce its expression. Figure 12 highlights p53 metabolic regulation.

Increased expression of p53 has been demonstrated to increase intracellular
ATP levels by up regulating oxidative phosphorylation as demonstrated in human colon
cancer cell line HCT116 with high p53 versus HCT116 cells depleted of p53 [126]. This
is achieved by increased expression of SCO2 a major component of the cytochrome c
oxidase complex in the ETC, complex IV. p53 also induces the expression of GLS2
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which converts glutamine to glutamate which can be used in the TCA cycle-ETC
pathway when metabolized to α-ketoglutarate to generate energy or glutamate could be
used in the synthesis of GSH to fight ROS stress [122]. Therefore, by increasing ATP
yield p53 down regulates glycolysis through allosteric inhibition of its enzymes,
previously reviewed. Wild-type p53 induces the transcription of p53-modulator-ofapoptosis (PUMA) and BCL2-associated X protein (BAX) [127]. These proteins work
together to create a pore in the outer membrane of the mitochondria and cause release
cytochrome-c, which is used to activate caspase-mediated apoptosis. There is an
interesting link between p53 and glycolysis, as it has been shown that increase glucose
uptake suppresses PUMA expression [128]. Furthermore, pAKT causes inactivation of
PUMA thereby enhancing glycolysis [129]. The role of p53 in regulation of cellular
metabolism is highly complex because of the plethora of cell functions associated with it.
PDAC p53 mutations targets its DNA binding ability while other protein-protein activity is
not altered, which will have an effect in p53 functions such as metabolic regulation.
Because of the prevalence of Warburg effect metabolism it is likely that mutant p53
plays a role in maintaining glycolysis it as evidenced by increased PPP metabolic flux in
PDAC or it may be that its metabolic regulating function is inhibited.

1. p53 regulates FA metabolism

FAs are important catabolic metabolic intermediates because they can undergo
beta-oxidation to generate acetyl-CoA, which produces energy through TCA-ETC
pathway [79]. Upon stress from DNA damage and glucose deprivation, p53 increases
the expression of guanidinoacetate N-methyltransferase (GAMT), which mediates the
conversion of glycine-derived guanidinoacetate to creatine for substrate level
phosphorylation of ADP thereby increasing ATP/ADP ratio, as it occurs in glycolysis.
Cancer cells can alter their metabolism by increasing de novo fatty acid (FA) synthesis
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irrespectively of the levels of extracellular lipids [130]. Similarly, increased expression of
FAO occurs in the livers of wild-type p53 mice, suggesting that p53 plays a role in
energy maintenance through the FAO pathway [131] and FASN is a conserved p53
target [132]. These observations suggest that wild-type p53 plays a role in linking FA
metabolism to FA synthesis while mutant p53 leads FA metabolism to oxidative
pathways. The role of mutant p53 in PDAC metabolic regulation has not been
elucidated.

Tumor Microenvironment Acidification
Water is universal solvent of life, with a high tendency to undergo self-ionization
[H20]ßà[OH-]+[H+]. However, free protons do not exist in solution so the equation is
fixed to [H20] ßà [OH-] +[H3O+]. The rate at which water ionizes (Kw) is defined by the
equation Kw=[OH-][H+]/[H20], which has been determined to be equal to 1.00 x
1014 mol2 dm-6 at 25°C and 2.4 1014 mol2 dm-6 at 37°C. Therefore, the potential
concentration of hydrogen ion [H+], pH, or hydroxide ion [OH-], pOH, at equilibrium is
defined by [OH-]x107+[H+]x107=[H2O]10-14. The pH and pOH can then be calculated by
taking the negative logarithm (-log) of the concentration (-log[H+] or -log[OH-] which means
that at equilibrium 7+7=14 since pH+pOH=Kw. However, because the body has an
internal temperature of 37°C and Kw=2.4 1014 mol2 dm-6, then the pH of water at body
temperature is calculated to be 6.8. The pH scale defines the concentration of H+ in
water solutions on a scale 1-14 with values <7 acidic and >7 basic. All biological
solutions have a certain concentration of protons from the balance between protonation
and deprotonation of water, weak acids, as well as, weak bases. For all living organisms
pH regulation is critical as it regulates all biochemical functions. Changes in pH alter 3dimential protein structures altering their function and inducing denaturation. Therefore,
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living organisms must maintain a narrow pH range through acid-base reactions, acids
donate protons and bases donate hydroxide ions. Acid-base reactions exchange
hydrogen ions with neutral molecules such as water (Arrhenius HA+H2Oßà A- + H30+)
and to electrically charged ions such as ammonium, hydroxide, or carbonate (Bronsted
Lowry HA + B ßà A- + HB).
The equilibrium between protons and unpronotated molecules can be described
by the acid dissociation equation, Ka, where Ka=[H+][A-]/HA]. Complex solutes such as
biological molecules i.e. proteins are often given several Ka values because of their
different proton binding sites. For this reason, the status of the protonatable site will vary
with respect to pH. For example, at low pH due to high [H+] all protonatable sites will be
filled, but with decreasing pH, low [H+], not all proton sites will be filled. Furthermore,
because any given molecule has multiple Ka it can be titrated by adding base
equivalents. Titration can be described by pH=pKa-log([HA]/[A-]) thus if the pKa is equal to
the pH the concentration of base and acid are equal. Thus, a molecule with multiple
protonatable sites also has multiple pKa values and isolectric points, pI= (pKa1-pKa2)/2,
useful to indicate the pronation status of a molecule at a measured pH. Molecules with
multiple protonatable sites are of major biological significance because they can function
as buffers useful in preventing major pH changes that would alter cell function. Indeed,
the sensitivity of proteins to pH changes is exceptional as it is a form of post-translational
modification therefore ionization of a key amino acid will alter protein function. For this
reasons, it is not surprising that only a narrow range of pH is permissible for livelihood of
eukaryotic cells. Reference:[109, 133]
Because of cellular metabolism, cells produce CO2 and lactic acids as a result of
metabolic activity cells are net acid producers and the pHi has a tendency to fall. This is
because lactic acid has a low pKa and deprotonates producing lactate- and H+ in
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physiological pH, which is slightly basic ~pH 7.4. Meanwhile, accumulation of CO2 will
promote its hydration to produce carbonic acid, which also has a low pKa relative to pHi
and will deprotonate to produce bicarbonate and release of a proton. Therefore, when
cells increased their metabolic rate they will face a dangerous challenge to maintain pHi
because buffers can only reduces amplitude of pH changes but cannot remove excess
protons. Thus, cells have to resolve to membrane transport. It is because the ability of
biological membranes to selectively allow the passage of molecules that gives rise to
difference between pHi and pHe, through selective transport of protons, as well as,
molecules that release or take up protons such as CO2 thereby effectively maintaining
pHi. The biological significance of protons highlights the essential function of regulating
pH and to adapt to pH changes. In the following sections I will describe the role of
metabolism and production of metabolic acids causing a decrease in pH of the TME.
Reference: [109, 133, 134].

pH of Cancer Cells
Physiological studies have established that oxygen and glucose diffusion in
human tumors is approximately at a radius of 200 µm and 280 µm from blood vessels,
respectively [135]. However, beyond the oxygen diffusion limit the tissue becomes
necrotic. However, hypoxic areas where oxygen tension is 1% or less is associated with
increase metastatic potential of cells and poor patient outcome. This is paradoxical in
terms of fitness considering that nutrients will also be less and the fact that cancer cells
proliferating cells require massive amounts of nutrients to generate biomass needed to
generate a daughter cells, as previously described [56]. In addition to the challenge of
oxygen and nutrient deprivation, cells in the PDAC TME must also endure the stress
from excess metabolic acids produced by proliferating cells. Indeed, TME acidification is
emerging as a hallmark of cancer [57]. Based on these observations it would be
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predicted that the pHi of cancer cells is acidic, but it has been measured to be
consistently above 7.1 so by this terms it is alkaline compared to pHe. This transmembrane distribution, pHi alkaline/ pHe acidic, of protons is not seen in normal tissues
that have a balance of pHi 7.2/ pHe 7.4 [57]. These observations instigate two questions
in cancer biology. First, how do cancer cells regulate tumor pH dynamics and, second,
how those pH distribution contributes to carcinogenesis?

The byproducts of metabolism in human cells are CO2 and lactic acid. If a cell
has a high concentration of CO2 its hydration will take place generating carbonic acid
whose pKa is 6.2 so it will deprotonate, CO2+H2OàH2CO3+H+. Similarly, lactic acid
produced through fermentation has a low pKa of 3.2 and it will also dissociate, lactic
acid+H2Oàlactate-+H3O+. Therefore, all cells are net acid producers; however, in living
organisms CO2 is moved out of cells through passive transport because of its high
lipid:water partition coefficient. Thus, CO2 modes into the capillaries where it is picked up
by red blood cells and removed through respiration. While, protons are charged
molecules and they cannot pass the lipid bilayer thanks to low lipid: water partition
coefficient. Passive transport of H+ via monocarboxylate transporters (MCT1,4). The rate
of CO2 and H+ venting depends on trans-membrane concentration gradients, which
physiologically are maintained by coupling with capillary blood, which delivers oxygen
and removes CO2. However, tumors are poorly perfused, especially PDAC tumors,
which considerably alters venting of protons and CO2. Because of venting impediment
the CO2 and H+ gradient will be high in the extracellular compartment thereby limiting
their passive effusion. In addition to extracellular buffers (proteins), cells have developed
adaptations to surpass the gradient rate-limiting step by cell surface expression of
carbonic anhydrases that accelerate the otherwise slow hydration of carbon dioxide,
CO2+H2OßàH2CO3ßàH+HCO3-, thereby facilitating CO2 and H+ venting, carbonic
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anhydrase (CA) mediates the hydration/anhydration step. Thus, hydration of CO2
requires mobilization of protons as well leading to increase in pHi and steady
acidification of pHe. However, due to its stoichiometry coupling H+ with lactate-, requires
an equal number of MCT proteins forcing cells to develop other means of transport
across the membrane to maintain pHi. This is critical for cancer cells with high metabolic
rate. Reference: [57, 133, 135, 136].

In a given concentration where the Ka and buffer concentration are kept constant
the only way of changing the pH is by adding base or acid equivalents, pKa=pH+pOH
and 14=pH+pOH. Where as in living cells the solution is provided with protons as a
result of metabolism. Thus H+/H+ equivalents only lowers the pH therefore cancer cells
must actively transport protons out of the cell or import their chemical equivalents HCO3or OH- to maintain pHi homeostasis. To balance pHi, membrane transporters must sense
pHi changes and lead to a H+/H+ equivalent efflux so that the pH remains constant. To
achieve this cells express membrane transporters to correct pHi disturbance such as:
Na+/H+ (NHE), H+ ATPase, Na+/HCO3- (NCB) transporter, which work against Cl-/HCO3exchanges (anion exchager, AE), and Cl-/OH- exchangers. Different types of transporters
are reported in various combinations in normal cells, but bicarbonate transporter appear
to be ubiquitous, were as, NHE appear to be cell type specific and dependent on
conditions of environment. Most of these transporters depend on electrochemical
potential of the molecules being transporter except for the H+ ATPase that hydrolyses
ATP. By coupling the activity of pH regulation membrane transporters with signaling
pathways cells can fine tune the metabolic response for steady state or
growth/proliferation in accordance to intrinsic (normal or oncogenic) or extrinsic factors
(growth factor, hormones, microenvironment). For example, NHE1 expression is
enhanced upon acidosis of extracellular space during hypoxia or upon low HCO3- levels
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in extracellular space. The signaling mechanisms inducing pHi control are still not
understood completely.

Active transport of proton equivalents is the way cancer cells prevent acidification
of pHi, despite substantial acid load to the TME. However, this mechanism has two
limitations being energy expenditure and pHe acidification. The energy commitment
challenges cancer cells because they have high ATP demand for cell functions and are
restricted to oxygen for oxidative metabolism. Therefore, pHi cannot operate at full
capacity as demonstrated by decrease in NHE activity when ATP levels are low.
Interestingly, the pH regulation system of removing proton equivalents does not
eliminate protons with base equivalents therefore net pHe acidification occurs since
tumor tissue is poorly vascularized, as in the case of PDAC. Even if it were possible to
maximize metabolic capacity in combination with pHi control system will result in
considerable acid load to TME, which will affect extracellular protein function as well as
damaging the feedback for passive transport via MCT and CO2 effusion. Therefore, in a
growing tumor pH dynamics are critical for survival of the cell as they are have to devote
energy for pH homeostasis and growth. Reference: [57, 133, 135, 136]. Figure 13
highlights the pHi regulators in cancer cells and a brief description is provided in table 2.

Hypothesis
Based on these observations, the evolutionary steps of carcinogenesis include 1)
acquisition of oncogenic mutation and its fixation to the tumor landscape 2) clonal
expansion of mutant cells 3) increase genomic instability leading to loss of tumor
suppressors i.e. CDKN2A or TP53 4) Upon loss of check point cell cycle regulation
stochastic growth of tumor cells may occur, but only cells that modulate the
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microenvironment by generating desmoplasia will undergo further selection to further
enhance fitness of cancer phenotype over immune cells and somatic cells; thereby
promoting cancer metabolic phenotype and metastasis. 5) Because of hypoxia, high IFP,
and oncogenic mutations cells are driven to adopt Warburg effect metabolism. 6) Cells in
hypoxic regions of the tumor continue to be selected and become the most aggressive,
but their survival is limited by regulation of pH dynamics, alkaline pHi and acidic pHe.
In the last stage of this proposed model of the somatic evolution of PDAC, two
factors fuel further growth and selection: metabolic phenotype and pH dynamics. PDAC
cells are selected to grow uncontrollably, but the fibrotic TME prevents efficient
ventilation of protons, which generates a challenge for regulation of pH dynamics. PDAC
cells are studied in pH-buffered conditions and little information is known about the
metabolic phenotype of cancer cells in low pH stress. Chapter 2 of this dissertation
describes the study of PDAC cells in chronic low pH stress. For these studies, I
hypothesized that in order to survive low pH stress the highly glycolytic PDAC cells must
modulate their metabolism to reduce proton load into the extracellular space. I predicted
a metabolic shift from Warburg effect metabolism and up-regulation of oxidative
metabolism resulting in reduction of TME proton load by PDAC cells experiencing
chronic low pH stress. These studies delve into the understudied low pH conditions of
the PDAC TME and its effects in cellular homeostasis. These studies are highly
significant to understand PDAC low pH stress response and identify therapeutic targets.
Figure 14 shows a picture representation of this hypothesis.
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Figure 1. Statistical data of PDAC diagnoses and survival rate. 1A) The ratio of
diagnose/survival ratio of PDAC and how it has remained unchanged over the past two
decades. 1B) The majority of PDAC cases are diagnosed as advanced disease, which is
associated with increased mortality. Seer database:
https://seer.cancer.gov/statfacts/html/pancreas.html [2].
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Figure 2. Changes of luminal pH in the exocrine pancreas during secretion. In
physiological conditions acinar cells secrete digestive enzymes and protons, which
acidify the acinar lumen. Ductal cells buffer the pH change by secreting bicarbonate.
Adapted from Hegyi et al. [28]
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Figure 3. Schematic representation of somatic evolution of cancer. Cells with mutations in
PDAC have more fitness than wild-type cells. If these mutations are gained, the more fit mutant
population will populate the tissue and may gain more mutations through injury or chronic
inflammation. Malignant transformation is the result of cells budding off from the tissue basal
membrane into the ductal lumen and modification of TME, which is the new selective force in
carcinogenesis. The bordered text indicates the subsequent tumorigenic steps of PDAC cells.
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Figure 4. Oncogenic KRAS and its downstream targets. Figure 4A. Wild-type KRAS
is regulated by GEF and GAP, which regulate the KRAS GTP-bound form. Figure 4B.
Oncogenic KRAS induces oncogenic signaling through ERK and AKT signaling
cascades. Adapted from Vasan et al. [137]

51

Figure 5. Function of CDKN2A gene products in cell cycle regulation. p16INK4A
functions in the RB tumor suppressor pathway through inhibition of CDK4/6 activity.
p14ARF inhibits E3 ubiquitilin ligase MDM2 thereby preventing degradation of p53. The
p53 pathway and RB pathway are integral in blocking inappropriate cellular proliferation.
Figure adapted from LaPak & Burd [138]
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Figure 6. p53 the guardian of the genome. The tumour suppressor p53 plays a
critical role in maintaining genomic stability, apoptosis mechanisms, metabolism, and
antioxidant defense. p53 is polyubiquitylated by the E3 ubiquitin ligase, MDM2,
leading to its proteasomal degradation. However, in response to stimuli such as
oxidative stress, hypoxia, oncogene activation and DNA damage, p53 becomes posttranslationally modified and stabilized to activate multiple pathways in response to
cellular stress. Depending on the severity of DNA damage, p53 can induce cell cycle
arrest, senescence, or apoptosis. p53 affects several metabolic pathways, including
glycolysis, the pentose phosphate pathway and oxidative phosphorylation.
Furthermore, p53 up-regulates antioxidant defense genes encoding reactive oxygen
species (ROS)-removing enzymes that are important for cellular and genetic stability
and thus contribute to the anti-tumour function of p53. Figure adapted from Siegl &
Rudel [139]
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Figure 7. PDAC progression. PDAC evolves from pre-malignant wellcharacterized histologically evaluated pancreatic lesions, pancreatic intraepithelial
neoplasms or PanINs. These pancreatic lesions are characterized by increased tissue
disorganization and gaining of malignant mutations. The genetic signature of PDAC
includes KRAS (PanIN-I) , INK4A (PanIN-II), TP53 (PanIN-III), and SMAD4 (PanINIII). Figure adapted from Iacobuzio-Donahue et al. [140]
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Figure 8. Summary of mammalian cell metabolism. In catabolic metabolism
nutrients are broken down to produce energy yielding metabolic by products. In
anabolic reactions chemical energy generated through catabolism is used to generate
building blocks of macromolecules through biosynthetic biochemical reactions.
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Figure 9. Canonical catabolic pathways. Glucose, amino acids, and fatty acids are
the main metabolic substrates for catabolic reactions. Amino acids can be
metabolized into pyruvate and/or metabolic intermediates of the TCA cycle. Lipids can
enter the TCA cycle through B-oxidation, a series of reactions where acetyl-coA is
released from fatty acids. Similarly glycerol can be metabolized to enter to enter
glycolysis metabolism as glyceraldehyde-3-phosphate. In this figure, the red circles
indicate enzymes that are regulated; 4-sided square boxes indicate complexes that
are regulated. In PDH complex the enzyme inhibiting is highlighted in red and the
enzyme that promotes it is highlighted in green. Blue arrow represents the reaction in
the opposite direction. Green boxes and green arrows represent the chemical energy
generated at the end of each pathway.
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Figure 10. Hypoxia inducible response leads to metabolic reprogramming.
Figure 10A. Stress factors regulate HIF1α stability through posttranslational
modification enabling stability of HIF1α allowing formation of the HIF complex through
interaction of HIF1α and HIF1β. The canonical mechanism of HIF1α stability is
hypoxia (in bold font). Decreased oxygen levels inhibit hydroxylation of HIF1α by
propyl hyrdoxylases (PHDs), which prevents its recognition by E3 ligase von HippelLindau (VHL), and subsequent proteasome degradation. When stable, HIF complex
binds HRE sequences to induced expression of target genes. Figure 10B. HIF target
genes include glycolysis rate limiting enzymes, glucose transporters, as well as, lactic
acid fermentation enzyme LDHA and MCT4 for rerelease of excess lactate. HIF also
increases expression of PDK which henbits PDH complex though phosphorylation
thereby uncoupling glycolysis from oxidative metabolism.
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Figure 11. Oncogenic is a master regulator of PDAC metabolism. KRAS diverts
glycolysis intermediates of metabolism into the HBP by inducing overexpression of
GFPT1. Similarly, KRAS induced expression of RPIA and RPE to divert glycolysis
intermediates to the non-oxidative PPP. KRAS also inhibits GLUD1 and
overexpresses GOT1 allowing glutamine to be metabolized through the non-canonical
pathway. Figure adapted from Perera & Bardeesy [141]

58

Figure 12. p53 mediated metabolic regulation. p53 regulates glucose catabolism in
cancer cells through effectors such as TIGAR, PGM, GLUT1/4, IKK, HKII, SCO2,
GLS2, and G6PD. These proteins work together to enhance oxidative metabolism and
reduce glycolysis and PPP. Figure adapted from Shen et al. [142]
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Figure 13. Major pH regulators in a cancer cell. Hypoxia and oncogenic driven
Warburg effect metabolic shift to increase lactate production from glycolysis or
glutamine. Similarly, reductive decarboxylation produces protons from excess CO2
(CO2+H2OàH2CO3àH++ HCO3-). CO2 moves passively across the plasma membrane
and is converted to carbonate by carbonic anhydrases. Protons are pumped out by
MCTs, NHE, and V-ATPase; while buffer (HCO3-) is imported by NBCs and AEs (BT).
Figure adapted from Damaghi et al. [143]

60

Figure 14. Hypothesis. In normal (physiological pH), PDAC cells are able to conduct

Warburg effect metabolism because cellular proton load into the TME is buffered.
Reduced buffering of pHe creates a significant difference between cytosolic-extracellular
[H+] gradient. In this conditions release of protons from metabolic reactions of glycolysis
will not be favored, as the electrochemical gradient will rather favor the inward flux of
protons. Cancer cell growth is stalled at pHi value bellow 7.2 further decrease in pH will
induce apoptosis. Thus, the cells must reprogram their metabolism to diminish production
of metabolic acids—lactic acid. Thus, they must switch to depend on oxidative
phosphorylation to make energy for cellular homeostasis in stress conditions.
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Table 1 A

Disease
Factor

Mutated
Genes

Hereditary breast and
ovarian cancer syndrome

BRCA1, BRCA2, PALB2

Lynch syndrome (hereditary
non-polyposis colorectal
cancer)

MLH1, MSH2, MSH6,
PMS2, EPCAM

Familial adenomatous
polyposis
Peutz-Jeghers syndrome

PDAC Increased Risk
2-3.5

8.6

APC

4.5-6

STK11/LKB1

132

Familial atypical multiple
mole melanoma pancreatic
carcinoma syndrome

P16INK4A/CDKN2A

47

Hereditary pancreatitis
Cystic fibrosis
Ataxia-telangiectasia

PRSS1, SPINK1
CFTR
ATM

69
3.5
Increased

Table 1B
Risk factor
Current cigarette use
Current pipe or cigar use
> 3 alcoholic drinks per day
Chronic pancreatitis
BMI > 40 kg/m2, male
BMI > 40 kg/m2, female
Diabetes mellitus, type 1
Diabetes mellitus, type 2
Cholecystectomy
Gastrectomy
Helicobacter pylori infection

Increased PDAC risk
1.7-2.2
1.5
1.2-1.4
13.3
1.5
2.8
2
1.8
1.2
1.5
1.4

Table 1. The risk of PDAC is elevated by intrinsic factors such as familial diseases
associated with loss of tumor suppressor genes and the risk of PDAC is also
elevated by extrinsic factors such as alcoholism and obesity. Table 1A. Intrinsic
factors associated with PDAC. Table 1B. Extrinsic factors associated with PDAC risk.
[144]
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Table 2

Name
Carbonic
Anhydrase II
Carbonic
Anhydrase IX

Carbonic
Anhydrase XII
Anion exchanger
Cl /HCO3
Sodium
bicarbonate
exchanger
Na+/HCO3-

Abbreviation
CAII
CAIX

CAXII
AE, SLC4
family

NBC family

Anion transporters

SLC26 family

Aquaporins

AQP

Sodium hydrogen
exchanger Na+/H+
Vacuolar ATPase
Monocarboxylate
Transporter 1

Monocarboxylate
Transporter 4

Description
Carbonic anhydrases catalyze the conversion of
carbon dioxide, the final product of oxidative
phosphorylation, and water to produce carbonic acid
which deprotonates in pHi to generate bicarbonate
and protons. CAIX and CAXII are transmembrane
CAs that has been identified to play roles in tumor
progression and metastasis. CAIX is a target of
HIF1α its expression is up regulated in hypoxic
regions of tumors. Intracellular CAs such as CAII will
dehydrate metabolically produced bicarbonate into
aqueous CO2 in a reaction consuming a proton
thereby promoting passive transport of CO2 [143,
145].
These transporters facilitate the movement of
−
HCO 3 ions across plasma membranes to either
acidify or alkalinize the pHi [143, 146].

NHE1
V-ATPase
MCT1

MCT4

NHE1 is the most common isoform of the
+
+
Na /H exchanger. NHE1 is the most active
transporter in pHi homeostasis. It uses the sodium
+
electrochemical gradient to extrude H when the
cytosolic pH becomes too acidic. NHE1 functions as
a pHi sensor during intense metabolic activity. NHE1
is known to be activated by EGF signaling as well
[143, 147].
V-ATPases pump protons out of the cytoplasm and
into intracellular vesicles such as lysosomes using
free energy from ATP hydrolysis [148].
MCTs transport mono-carboxylic acids such as
lactate, pyruvate, and ketone bodies into and out of
cells across plasma and mitochondrial membranes.
Only 4 isoforms, MCT1–MCT4, have been
functionally characterized as proton-linked
monocarboxylate transporters. MCT1 and MCT4 are
commonly overexpressed in tumors as they are
essential in regulating the cytosolic efflux of lactate
and protons produced through HIF or Warburg effect
up-regulated glycolysis. Therefore, their expression
is critical to maintain pHi homeostasis at the expense
of contributing to extracellular acidosis [145, 149].

Table 2. Membrane transporters regulating pH i.
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Chapter 2
Results:
GOT1-Mediated Anaplerotic Glutamine
Metabolism Regulates Chronic Low pH
Stress in PDAC Cells
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Introduction
Metabolic alterations represent an important hallmark of cancer cells [150].
Metabolic reprogramming allows cancer cells to sustain uncontrolled proliferation by
rapid generation of ATP, biosynthesis of macromolecules, and maintenance of redox
status [151]. Cancer cells can also reprogram the major metabolic pathways
(carbohydrates, proteins, lipids, and nucleic acids) in order to meet these basic demands
for uncontrolled proliferation [56, 152]. The characteristic metabolic phenotype seen in
cancer cells is the Warburg effect, which operates by enhancing glucose uptake and flux
into glycolysis, while simultaneously diminishing the glucose carbon flux that enters the
TCA cycle in the mitochondria, even in the presence of oxygen [36, 153]. Although ATP
generation through substrate level phosphorylation is very rapid, this mechanism is far
less efficient than oxidative phosphorylation in generating energy from glucose. Thus,
the metabolic phenotype observed in the Warburg effect demands very high glucose
uptake to meet the energetic, biosynthetic, and redox needs of cancer cells. For this
reasons the increased glucose uptake of cancer cells is useful for diagnosing cancer
using radiolabeled glucose analog 18F-fluorodeoxyglucose and positron emission
tomography (FDG-PET) to image and evaluate tumor progression without the need of a
biopsy [154, 155].
Because of the enhanced metabolic rate of rapidly proliferating tumor cells, the
glucose that is metabolized through substrate level phosphorylation produces lactic acid
as the end product. Lactic acid is a weak acid with pKa with approximately ~pH 4, and
thus, it quickly dissociates loses a hydrogen ion [156]. Lactate is transported outside of
the cell by monocarboxylate symporters along with protons resulting in decreased pH in
the extracellular milieu [157, 158]. Intracellular hydrogen ions can also be removed by
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sodium hydrogen exchangers that import sodium ions and extrude hydrogen ions,
thereby acidifying the extracellular environment [159, 160]. Similarly, vacuolar ATPases
extrude hydrogen ions against their concentration gradient to the extracellular space,
and hence, lower the extracellular pH [161]. In vitro studies have shown that rapidly
growing cells, which exhibit the Warburg effect, increase the expression of these cell
surface proteins to maintain an alkaline intracellular pH environment [57, 162]. Indeed,
increased intracellular pH is an established permissive signal for cellular proliferation
promoting survival by limiting apoptosis, a process that is associated with intracellular
acidification [163, 164]. The role of low extracellular pH in carcinogenesis is thus
paradoxical: on one hand alkaline intracellular pH promotes proliferation and survival,
while at the same time, extracellular pH promotes invasion and metastasis at the cost of
inducing stress, senescence, and apoptosis [159, 165, 166].
In addition to glucose, glutamine metabolism is also essential for the proliferation
of cancer cells. Recent studies have demonstrated that glutamate derived from
glutamine is utilized by highly proliferative cells to generate non-essential amino acids
(NEAAs) through the glutamic-oxaloacetic transaminase enzymes (GOT1 and GOT2),
while quiescent cells metabolize glutamate through GLUD1 (glutamate dehydrogenase
1) and subsequent decarboxylation reactions in the TCA cycle [167, 168]. Thus,
glutamine can be metabolized through both anabolic (anaplerotic) and catabolic
pathways.
Several oncogenes are implicated in reprogramming tumor cell metabolism. One
such gene is KRAS, which upon accumulating activating mutations serves as a key
signature oncogene that serves a prominent role in malignant transformation and tumor
progression in PDAC [5, 169]. PDAC cells with oncogenic KRAS have reprogrammed
glucose and glutamine metabolism to serve anabolic processes [96, 108]. Canonical
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glutamine metabolism occurs through glutamate synthase (GLS)-mediated conversion of
cytoplasmic glutamine into glutamate. Glutamate is then metabolized in the mitochondria
through GLUD1 into alpha-ketoglutarate that enters the TCA cycle [170]. The noncanonical pathway metabolizes glutamate to aspartate and alpha-ketoglutarate through
GOT2; aspartate is subsequently metabolized to oxaloacetate by GOT1 in the cytosolic
compartment. Aspartate is metabolized by malate dehydrogenase (MDH) to malate,
which is then metabolized by malic enzyme (ME) to produce pyruvate. These anaplerotic
reactions increase the NADPH/NADP ratio thereby maintaining ROS balance. PDAC
cells are dependent on these reactions for maintenance of intracellular ROS levels as it
is evidenced by the decrease in cell survival upon knockdown of enzymes in the
pathway.
Due to metabolic reprogramming by oncogenic KRAS present in 90% of PDAC
cases, extracellular acidification is highly abundant. While the regulation of pH in cancer
cells has been studied thoroughly, the metabolic adaptations to chronic low ph induced
stress are not well defined. Therefore, in the current study, we investigated the metabolic
basis of adaptation to chronic low pH stress in PDAC cells, which exhibit high glycolytic
capacity, by subjecting them to chronic low ph. We utilized PDAC cells with oncogenic
KRAS to identify the metabolomic alterations in PDAC cells under chronic low ph and
identify vulnerabilities for therapy. Here, we report a pronounced increase in noncanonical anaplerotic glutamine metabolism, which serves the bioenergetic needs and
maintains ROS balance in cells undergoing acidosis stress.

Materials & Methods
Cell lines:
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Cell culture of PDAC cell lines S2-013 and Capan-1 have been described
previously [93, 171]. The S2-013 and capan-1 cell lines were obtained from a liver
metastases of PDAC patients. In immunodeficient nude mice orthotopic implantation,
Capan-1 and S2-013 forms a tumor that produces mucin and is morphologically and
biochemically similar to the PDAC tumor of origin. Capan-1 and S2-013 cell lines both
bear activating KRAS mutation, mutant TP53 affecting p53 DNA binding, and
homozygous deletion of CDKN2A/p16. While, SMAD4 has no alterations and Capan-1
have shallow deletions, cosmic database. Cells were validated by STR profiling.
Control pH culture:
Cell lines were cultured in high glucose high glutamine Dulbecco’s Modified
Eagle Medium (DMEM) (Hyclone) containing 4.5g/L glucose (Sigma-Aldrich) and
0.584g/L glutamine (Sigma-Aldrich). Additionally, 1mM sodium pyruvate and 5% FBS
were supplemented to complete the media. To set control pH 3.7g/L NaHCO3 were
used, this concentration sets pH of media approximately to ~7.4 at 37 degrees Celsius,
and phenol red in DMEM indicates pH changes. The media was replaced every 24hrs to
maintain pH from metabolic acids produced by cell growth.
Low pH cell culture:
Cell lines were cultured in high glucose high glutamine Dulbecco’s Modified
Eagle Medium (DMEM) (Hyclone) containing 4.5g/L glucose (Sigma-Aldrich) and
0.584g/L glutamine (Sigma-Aldrich). Additionally, 1mM sodium pyruvate and 5% FBS
were supplemented to complete the media. To set low pH conditions 1g/L NaHCO3 were
used, this concentration sets pH of media approximately to ~6.9-7 at 37 degrees
Celsius, and phenol red in DMEM indicates pH changes. Low pH media with values 6.7
and 6.4 was prepared using 0.5 and 0.1 g/L NaHCO3 respectively. The media was
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replaced every 24hrs to maintain pH from metabolic acids produced by cell growth.
Lactic acid was used to decrease the pH of media, but the pH was very inconsistent
being very acidic without sodium bicarbonate and titration with bicarbonate or hydroxide
equivalents. The organic zwitterionic organic chemical buffer HEPES (4-(2hydroxyethyl)-1-piperazineethanesulfonic acid) was used as well, but it required addition
of HCl equivalents to lower the pH to 7.0 and it was not maintained in the incubator. To
establish chronic low pH exposure, cells were cultured in pH 6.9~7.0 continuously for 14
days using bicarbonate as the buffer of choice. The media was changed every 24 hours
during this period.
pH maintenance during in vitro incubation:
The pH value of the media is critical for growth of cells in culture and should be
buffered to pH 7.4 in order to replicate physiological conditions. Thus the conditions in
the incubator are 20% oxygen, same as atmosphere, and 5% for CO2 to replicate blood
levels, 40mmHg. Oxygen is not a polar molecule therefore it will not dissolve in water,
but CO2 will dissolve in water forming carbonic acid. However, because the pH of 1L
DMEM is 6.6 without NaHCO3, carbonic acid will quickly dissociate because of its acid
dissociation constant (Ka) being lower than that of the pH of the media producing
bicarbonate and protons. Furthermore, Henry’s law of gas solubility states that at a
constant temperature of 37°C the amount of CO2(g) that dissolves in the media is
directly proportional the partial pressure of CO2(g) in equilibrium with the media.
Therefore, conversion of gas to aqueous CO2 is described in the following equation, CO2
(aq)ßàCO2(g)+H2O(l), at constant equilibrium (Keq) conversion is defined by
Keq=[CO2(g)[H2O(l)]/[CO2(aq)] and assuming that water concentration is constant we can
define the equation as a dissolving constant of gas pressure, KH, which also defines the
partial pressure of the gas that is dissolved thus KH=Keq/[H2O]=pCO2/[CO2(aq)]. In this
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way the equilibrium constant can be calculated for 1M of CO2 which is KH=29.41 and
applying this to the 5% CO2 in the incubator which equates to 38mmHG or 0.5 ATM the
amount of dissolved CO2 gas in the incubator is 1.7x10-3M, KH=pCO2/[CO2(aq)] then
[CO2(aq)]=pCO2/KH. Therefore, CO2 (g) gas that dissolves in the incubator will exist as
bicarbonate HCO3- , CO2(g)+H2OàH2CO3à HCO3-+ H3O+. For this reason, to replicate
physiological pH of 7.4 the pH must be adjusted using buffers systems such as naturalbuffer system by adding bicarbonate and/or chemical buffering using zwitterions. For this
study I opted to buffer pH using the natural-buffer system (bicarbonate). The human
body has a reserve of NaHCO3, from kidney, and plenty of HCO3- circulating in the
blood, which is very useful to maintain blood pH at 7.4 by removing protons using the
vascular system. Protons generated from metabolic acids combine with HCO3- to form
H2CO3, because of the increased concentration of bicarbonate the reverse reaction
occurs and carbonic acid is converted to CO2 and water. Excess CO2 in blood is picked
up by red blood cells (RBC) and undergoes the following reaction
CO2+H2OàH2CO3àHCO3-+H+ with the first reaction catalyzed by carbonic anhydrase
(CA). This mechanism is essential for delivery of oxygen to tissues because increased
protons in RBCs reduces hemoglobin binding affinity to O2 causing its release into
tissues. At the same time cells exchange HCO3- for Cl-, through anion exchanger (AE),
thereby increasing plasma CO2 and maintain a high pCO2 for O2 delivery. In the lung,
pO2 increases and forces protons of Hb allowing O2 to bind Hb. The accumulation of
protons leads to a shift in AE and bicarbonate is imported and combines with protons to
form carbonic acid that is converted to water and CO2 by CA, H++HCO3àH2CO3àCO2+H2O. The human body is an open system and CO2 is removed as gas
from lung alveoli. However, cells in an incubator are not an open system and media
must be changed to maintain constant pH since buffers can only contain excess
accumulation of protons not remove them. The pH of control media was set to ~7.4
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using 3.7g/L of NaHCO3, which dissolves in the media to form sodium ions and
bicarbonate (NaHCO3àNa+ + HCO3-). The pKa of carbonic acid is 6.4 and carbonate is
10.2 indicating that the isoelectric point is 8.3, pI=1/2(pKa1+pKa2). Therefore, at pH 7.4
the solution contains a higher amount of bicarbonate than at pH 7.0, therefore the higher
concentration of NaHCO3 has more base equivalents to counter metabolic acids for a
longer time. Reference: [172].
GOT1 Knockdown:
Cell transfections for producing replication-incompetent lentivirus were performed
by utilizing Turbofect followed the manufacturer’s protocol [93, 173]. Stable short hairpin
RNA (shRNA) constructs were obtained from Sigma-Aldrich: shGOT1 (34784;
CCGGGCGTTGGTACAATGGAACAAACTCGAGTTTGTTCCATTGTACCAACGCTTTTT
G) and shGOT1 (34785; CCGGGCTAATGACAATAGCCTAAATCTCGAGATTTAGGC
TATTGTCATTAGCTTTTTG). Cells were transfected in control pH culture conditions and
after puromycin selection and knockdown validation clones were plated in low pH for 14
days to establish chronic low pH expossure. Cells were validated by STR profiling.
Metabolomics:
Polar metabolite isolation was performed as described previously [174]. In short,
0.75×107 cells were cultured for 24h in normal DMEM. Cells were then washed with PBS
and culture medium was exchanged with fresh medium 2 hours before metabolite
extraction, the pH of the media was maintained. Cells were frozen in dry ice and polar
metabolites were then extracted with 80% methanol by plate scraping. Metabolite
extracts were subjected to LC-MS/MS analysis using multiple reaction monitoring
methods described previously [175]. Data acquisition was carried out utilizing
AnalystTM1.6 software (AB SCIEX) and peaks were integrated with MultiquantTM (AB
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SCIEX). Peak areas were normalized to the respective protein concentrations in both
culture conditions. Extraction and analysis of polar metabolites was performed three
times after cells had been grown in low pH for 14-days.
Reactive oxygen species assay:
Reactive oxygen species levels were determined by using oxidation-sensitive
fluorescent dye 2’,7’–dichlorofluorescin diacetate (DCFDA). Control and low pH cells
were seeded at 3.0×104 cells per well in a clear bottom black 96-well plate. After the cells
adhered, the media was replaced with fresh DMEM containing 10 µM DCFDA, with or
without respective treatments. H2O2 was used as a positive control and N-acetyl cysteine
(NAC) was used as a negative control. Control and treated cells were incubated at 37°C
for 30 mins. The cells were washed with PBS and 100µL of PBS was added to the wells
for measuring the emission of DCFDA using Biotek Cytation3 plate reader. DCFDA was
measured using an excitation of 495nm and an emission of 529nm. These experiments
were repeated two times with similar results. The same experiment was repated using
ROS-insensitive dye 5(6)-Carboxy-2’,7’-dichlorofluorescin diacetate (CDCFDA) as a
negative control and H2O2 as a positive control.
Growth Kinetics:
To determine growth kinetics, 2.5×105 cells were seeded in 12-well tissue culture
plates in control and low pH media. These cells were trypsinzied at 24, 48, 72, and 96
hours after cells were attached to the plate. If cells received treatment, this was reapplied every 24 hours. Once collected, cells were stained with trypan blue (Gibco) and
counted using BioRad TC20 automated cell counter.
Colony formation assay:
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Cells were seeded in 6-well tissue culture plates at 200 cells per well or in 12well plates at 50 or 100 cells per plate. Cells were allowed to attach to the plate for 48
hours and then media replaced with fresh media every 72 hours. Colonies were allowed
to form for 14 days. Colonies formed at the end of experiments were washed, fixed in
methanol, and stained with 0.4% crystal violet in 25% methanol. Colonies containing >50
cells for each well were counted. This experiment was repeated with 100 and 200 cell
numbers showing similar results.
Cell cycle analysis:
Cell were seeded at 20% confluence in 60mm tissue culture plates and allowed
to adhere to the plate overnight. Cell growth was synchronized using the double
thymidine block previously described [176]. After synchronization, cells were cultured in
fresh media for approximately 20 hours before collection for cell cycle analysis. Cells
were fixed with cold ethanol and stained with Telford reagent (16.81mg EDTA, 13.4 mg
of RNAse A, 25mg of propidium iodide, and 500µL of Triton X-100, dissolved in 500mL
of milli-q water). These samples were submitted for analysis to the University of
Nebraska Medical Center flow cytometry research facility. This experiment was repeated
twice yielding similar observations.
Glucose/Glutamine Uptake:
Cells were seeded at a density of 5×104 cells per well in 24-well plates and
allowed to adhere overnight before conducting the experiment. Cells were cultured in
glucose and glutamine, and pyruvate containing DMEM and 5% fetal bovine serum.
Cells were seeded in eight replicates 3 for background, 1 for counting (normalizing), and
4 for radiolabeled metabolite uptake. For the glucose uptake assay the cells were
starved for 2 hours in DMEM without glucose, glutamine, pyruvate, and fetal bovine
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serum. After 2 hours the background wells were supplemented with 50x the normal
concentration of glucose for 20 minutes. Control and low pH cells were then incubated
with tritiated [3H]2-Deoxy glucose, washed with PBS, and lysed with 1% SDS. The
lysates were counted for [3H] by a scintillation counter. For glutamine uptake assay, cells
were incubated with [3H] glutamine, but background cells were not. Cells were
subsequently washed with PBS, lysed with 1% SDS and lysates were counted for [3H] by
a scintillation counter. These experiments were repeated three times with similar results.
Lactate Release:
Control and low pH cells were seeded in 24-well plates at 5×104 cells. After 12h,
the culture medium was replaced with fresh phenol red free DMEM set to pH 7.4 and pH
7.0. Cells were cultured for 24h and the culture supernatants were then used to
determine lactate release by lactate assay kit (Eton Bioscience Inc., San Diego, CA,
USA), per manufacturer protocol. This experiment was repeated twice yielding similar
observations.
ATP assay:
Cells were seeded at 5×105 cells per well in a 12-well tissue culture plate. The
cells were maintained in control and low pH DMEM. After 24 hours, cellular ATP levels
were determined using an ATP assay kit (Roche, Indianapolis, IN, USA) following the
manufacturer’s protocol. Values were normalized to the cell counts. This experiment was
repeated twice yielding similar observations.
Cytotoxic assays:
Cells were seeded at 5×103 in 96-well plates or at 2.5×105 in 12-well plates. Cells
were treated for 72 hours after they attached. The MTT assay was used in 96-well plate
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culture and trypan blue stain and counting were used for cells in 12-well plate culture.
GraphPad Prism statistical software was used to calculate inhibitory concentration.
These experiments were repeated three times with similar results.
Quantitative real-time PCR:
Cells were cultured in 60mm dishes for RNA extraction using Trizol (Life Technologies)
and cDNA was prepared using Thermo Scientific Verso cDNA Kit following
manufacturer’s protocol. RT-qPCR was performed using Roche FastStart Universal
SYBR Green Master Mix (Roche) following the manufacturer’s protocol. These
experiments were repeated three times with similar results.
Growth Kinetics:
To determine growth kinetics, 2.5×105 cells were seeded in 12-well tissue culture
plates in control and low pH media. These cells were trypsinized at 24, 48, 72, and 96
hours after the cells attached to the plate. If cells received treatment, this was re-applied
every 24 hours. Once collected, cells were stained with trypan blue (Gibco) and counted
using BioRad TC20 automated cell counter. These experiments were repeated three
times with similar results.
Data analysis:
Student’s t-test was used to compare data between two groups. Two-way
ANOVA was used to compare data from multiple groups defined by two variables. When
results are significant, post-hoc analyses with Bonferroni method for multiple
comparisons were conducted. All data analyses were conducted using Graphpad Prism
5.
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Results
PDAC cell growth is diminished in low pH conditions
Intracellular pH value is known to have a significant role in conveying proliferation
and death signals [57]. For example, it has been observed that proliferating cells require
an intracellular alkaline pH value greater than 7.2, to allow for growth-factor stimulated
cells to enter the S-phase of the cell cycle at a faster rate, and proceed to the G2 and M
phases more rapidly [177, 178]. Furthermore, a higher pH is known to suppress mitotic
arrest due to activated DNA damage checkpoints; therefore, maintaining an alkaline
intracellular pH enhances bypassing of cell cycle checkpoints allowing cells to have
unrestricted proliferation [179, 180]. While intracellular acidic pH promotes pro-apoptotic
BAX by enhancing conformational changes that facilitate mitochondrial insertion thereby
increasing pore formation allowing increased permeability to the mitochondria and
release of pro-apoptotic proteins such as cytochrome-c into the cytosolic compartment
[181]. PDAC cells in culture (pH 7.4) exhibit the Warburg Effect [93]. Hence, we
investigated whether chronic low ph of extracellular milieu would have an effect on cell
growth. To address this question we determined the growth kinetics of PDAC cell lines
(S2-013 and Capan-1) in various acidic pH values of tumors reported in the literature
and identified that the pH value between 6.9-7.0 resulted in significant growth reduction
when compared to the physiological pH (Fig. 1A). To determine if reduced growth in low
pH is due to reduced clonogenicity we conducted colony formation assays and identified
that cells in low pH culture have reduced clonogenicity compared to the cells that are
cultured in control pH (Fig. 1B). Subsequently, we synchronized growth of cells cultured
in control and low pH conditions with a double thymidine block and released them for 20
hours before collecting them to be fixed and stained with propidium iodide, to determine
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DNA content using flow cytometry. We identified that cells in the G1/G0 phases are
significantly increased in low pH culture; we further observed decreased percentage of
cells in the S and M phases (Fig. 1C). This data indicates cell cycle arrest in the G1/S
transition in PDAC cells in the low pH environment that results in reduced rate in cell
cycle progression and growth.
Reduced glucose uptake and metabolism in low pH conditions

Rapid growth and progression through the cell cycle is associated with upregulation of glycolysis. We thus performed [3H] glucose uptake assays and determined
that cells in low pH culture have a significant reduction in glucose uptake compared to
cells in control pH (Fig. 2A). We also conducted a lactate release assay and found that
in chronic low pH exposure there is a significant reduction in lactate release (Fig. 2B). To
determine if the reduction in glucose uptake and lactate release was due to a decrease
in glycolysis, we isolated polar metabolites from cells in both control and low pH culture,
and conducted liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS)based metabolomics analyses. Our LCMS analysis demonstrated that glycolysis
metabolites are significantly reduced in low pH (Fig. 2C). Collectively, our data
demonstrates a clear departure from the classic Warburg Effect metabolic phenotype.

Increased oxidative phosphorylation in low pH conditions

Our metabolomics data also demonstrated that cells in low pH have active
mitochondrial metabolism (Fig. 3A). As a parallel nutrient source, glutamine is essential
in oxidative metabolism because it can be metabolized to generate alpha-ketoglutarate
and enter the TCA cycle [170]. To evaluate if alterations in glutamine metabolism
complement for the reduced glucose metabolism, we next evaluated glutamine uptake.
We supplemented cells with [3H] glutamine and observed that cells in chronic low ph
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stress have a significant increase in glutamine uptake (Fig. 3B). To determine if the
increase in glutamine uptake had an effect on oxidative metabolism and ATP generation
we collected cell lysates from cells cultured in low pH and control pH conditions, and
observed that cells in low pH generate significantly more ATP than cells in control pH
culture (Fig. 3C). Next, we treated both control and low pH cells with oligomycin, an
inhibitor of complex V (ATP synthase) in the electron transport chain, which acts by
blocking the channel formed by the F0 complex of ATP synthase inhibiting H+ movement
down its concentration gradient, thereby preventing ATP synthesis [182]. Treatment of
cells in control and low pH with oligomycin showed that cells in low pH are much more
sensitive than cells in control pH, by several orders of magnitude (Fig. 3D). These data
demonstrate that chronic low ph influences a metabolic shift that enhances glutamine
metabolism over glucose metabolism resulting in a change in ATP generation from
substrate level phosphorylation to oxidative phosphorylation.

Increased glutamine metabolism in low pH conditions

Metabolomic analysis identified a significant increase in the levels of metabolites
involved in non-canonical glutamine metabolism in S2-013 and Capan1 cells cultured
under chronic low pH (Fig. 4A). Furthermore, RT-qPCR analysis demonstrated
increased mRNA levels of genes involved in non-canonical anaplerotic glutamine
metabolism under chronic low ph conditions (Fig. 4B). To further validate these
observations, cells in control and low pH were treated with metabolic inhibitors targeting
canonical and non-canonical glutamine metabolism. Cells were treated with
aminooxiacetic acid (AOA) and epigallocatechin gallate (EGCG) to inhibit the
transaminase enzymes (GOT1, GOT2) and GLUD1, respectively. We determined that
the cells in low pH were at least an order of magnitude more sensitive to AOA treatment
(Fig. 4C); however, the inhibitory concentration of EGCG was only modestly different in
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control and low pH (Fig. 4D). Hence, our data indicate that cells with chronic low ph
develop a metabolic phenotype that is highly dependent on anaplerotic glutamine
metabolism, as demonstrated by increased metabolite levels, enzyme transcription, and
increased sensitivity to a transaminase inhibitor (Fig. 4E).

GOT1 counters ROS production under low pH conditions

Anaplerotic glutamine metabolism can provide the fuel for proliferation by
generating ATP through the TCA cycle, generation of NADPH for redox reactions, and
production of NEAAs used in protein biosynthesis [108, 168, 170]. Thus, we speculated
that up-regulation of anaplerotic glutamine metabolism is required for maintenance of
cellular homeostasis during stress induced by chronic low ph. Based on our
metabolomics analysis, we predict that due to the low glycolytic rate observed in chronic
low ph the flow of metabolites into the pentose phosphate pathway for generation of
glycolysis derived NADPH is reduced. Therefore, anaplerotic glutamine metabolism is
essential for ROS suppression in low pH. Furthermore, we identified increased GOT1
levels in low pH and as previously stated GOT1 is the first enzyme in the glutamine
anaplerotic pathway and its metabolic reaction allows glutamate-derived aspartate to be
metabolized and generate NADPH for ROS suppression. To determine this, we
generated stable knockdowns of GOT1 (Fig. 5A). Recent reports have shown that GOT1
and glutamine reprogramming are increased in PDAC [183]. Of note, under control pH
conditions, we observed minimal growth inhibition in GOT1 knockdown cells, compared
to control shRNA-transfected cells. However, GOT1 knockdown cells demonstrate
significant growth inhibition compared to control cells in low pH (Fig. 5B-C). The most
prominent PDAC phenotype we have observed in low pH culture is the increase in
oxidative metabolism, which can lead to a substantial increase in reactive oxygen
species (ROS). ROS are diverse in their functions, and depending on their concentration
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they may have different outcomes [184]. For instance, low concentrations of ROS may
induce proliferative signaling and activation of survival pathways, but at high levels, there
is ROS-induced pathology due to damages in DNA, proteins, and lipids, as a result,
oxidative damage may result in growth inhibition, senescence, and cell death [185-189].
We measured ROS levels (HO, 1/2 O2, H2O2) using 2,7-dichlorofluorescin diacetate
(DCFDA) and found that GOT1 knockdown cells in low pH have significantly higher
levels of ROS than control cells in alkaline pH (Fig. 5D). To further validate these
observations we measured intrinsic ROS levels and ROS levels induced after hydrogen
peroxide supplementation using DCFDA. We utilized the ROS-insensitive dye 5(6)Carboxy-2’,7’-dichlorofluorescin diacetate (CDCFDA) as a negative control and H2O2 as
a positive control (Fig. 5E). Of note, the inhibition of non-canonical glutamine metabolism
by GOT1 knockdown results in increased ROS levels, which are further increased in low
pH culture conditions. We conclude that cells in low pH generate more ROS that are
increased upon inhibition of anaplerotic glutamine metabolism due to decreased GOT1.

Cancer cells are known to have increased expression of enzymes that suppress
high ROS levels to prevent senescence and/or apoptosis [190-192]. ROS production can
be increased by oxidation of nicotinamide dinucleotide phosphate (NADPH) by NADPH
oxidase enzymes (NOX). It can also be increased through mitochondrial electron
leakage, generating increased superoxide levels [151]. Superoxide levels are reduced
by superoxide dismutases (SOD) that can combine superoxide radicals with water to
produce hydrogen peroxide (H2O2), which in turn is capable of initiating redox biology by
oxidizing cysteine residues of proteins and initiate signaling events [193]. By LC-MS/MSbased quantification, we analyzed the redox status of the most abundant antioxidant
molecules NADPH and GSH. Our analysis revealed that the NADP/NADPH ratio is very
similar in both alkaline and acidic pH conditions, but the glutathione disulfide/glutathione
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(GSSG/GSH) is much higher in cells cultured in low pH (Fig. 5F). These data indicate
that the antioxidative capacity of GSH is lesser in low pH. In rapidly proliferating cells,
NADPH is mainly produced from glycolysis in the pentose phosphate pathway, with
smaller contributions from isocitrate dehydrogenase and malic enzyme [151]. Our RTqPCR analysis of the enzymes involved in anaplerotic glutamine metabolism showed
that the malic enzymes ME1 and ME2 have a significant increase in transcription in low
pH (Fig. 4B). We also performed RT-qPCR of the enzymes involved in antioxidant
metabolism, and identified a very prominent increase in the expression levels of NOX1,
NOX2, and NOX3 in GOT1 knockdown cells cultured in low pH, in comparison to control
shRNA-transfected cells (Fig. 5G-I). Of note, these transcript level differences are not
compensated by an increase in SOD1/SOD2 mRNA levels (Fig. 5J-K). Therefore, cells
with GOT1 knockdown are unable to withstand low pH microenvironment due to
generation of cytotoxic ROS levels.

Oxaloacetate can rescue GOT1 knockdown cells under low pH
The reaction carried out by GOT1 uses aspartate as a substrate and converts it
into oxaloacetate (OAA) [108]. Hence, we supplemented knockdown cells in low pH with
oxaloacetate to re-establish anaplerotic glutamine metabolism and allow knockdown
cells to suppress ROS. As a positive control of ROS suppression, we supplemented
cells with N-acetyl cysteine (NAC; a ROS quencher), and aspartate and alanine, the
non-essential amino acid products of this pathway, were used as negative controls. The
growth of cells in low pH was compared to the cells supplemented with 3mM of NAC,
2mM of OAA, or 0.1mM of NEAA for 96 hours. Our results indicate that both NAC and
OAA enhance cell growth and colony formation in low pH under GOT1 knockdown
conditions, while supplementation with NEAA had no effect (Fig. 6A-B). To determine if
OAA treatment has the same effect as NAC in decreasing ROS levels we supplemented
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cells with OAA, NAC, and H2O2 to subsequently measure ROS levels using DCFDA. Our
results showed that only the cells with GOT1 knockdown cultured in low pH have
decreased ROS levels when supplemented with 2mM of OAA (6C). Thus, our data
indicates that inhibition of anaplerotic glutamine metabolism by removing GOT1 results
in increased ROS levels and the addition of OAA rescues cell growth by resuming this
metabolic pathway.

Discussion
Acidification of the tumor microenvironment is a common feature of PDAC (and
of most epithelial tumors). Understanding the metabolic changes that PDAC cells
undergo due to acidosis stress is extremely important in designing more effective
treatments. Our metabolomic analysis shows that cells in low pH depart from Warburg
effect metabolism, and that they increase anaplerotic glutamine metabolism to allow
cells to generate vast amounts of ATP, which in turn allows for maintaining cellular
homeostasis during acidosis stress. We demonstrate for the first time that anaplerotic
glutamine metabolism-mediated countering of ROS levels serves as the survival
mechanism for pancreatic cancer cells under chronic low ph.
Glucose and glutamine are the primary nutrients for cancer cells; however, only
glutamine can provide both carbon and nitrogen [194]. Indeed, glutamine is an important
growth signal [195]. Furthermore, glutamine can be metabolized into products such as
nucleic acids, glucosamine, and NEEAs [195]. Based on our experiments to determine
cell growth in low pH and rescue of cell survival with oxaloacetate upon GOT1 depletion,
we believe that utilization of glutamine under low pH stress is not meant to induce
growth signals or biosynthesis of macromolecules instead it is used for energy
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biosynthesis to maintain homeostasis through moderation of high ROS levels stressing
the cells.
Recent studies have demonstrated the advantages of non-canonical glutamine
metabolism over the canonical pathway. In the study conducted by Coloff et al, it was
demonstrated proliferating cells could take advantage of metabolism through the
transaminase enzymes, whereas, quiescent epithelial cells have decreased
transaminase expression; furthermore, glutamine metabolism is diverted to GLUD
diminishing the biosynthetic potential of glutamine metabolism [168]. Similarly, in the
study by Son et al. it was demonstrated that oncogenic KRAS plays a significant role in
glutamine metabolic reprogramming in PDAC through the transcriptional upregulation of
GOT1 and inhibition of GLUD1 expression [108]. Furthermore, this and other studies
reveal the role of non-canonical anaplerotic glutamine metabolism in the generation of
NADPH and possibly ROS regulation through coupling with other redox balance
pathways such as glutathione synthesis [108, 196]. Here, we have shown that PDAC
cells have the potential to reprogram metabolic pathways allowing them to maintain
homeostasis in acidosis stress conditions.
In our studies, the increase of ROS levels is primarily due to leakage in
mitochondrial superoxides from up-regulation of oxidative metabolism during low pH
stress and also from up-regulation in the transcription of NADPH oxidases. For this
reason, PDAC cells develop increased ROS levels that result in reduced proliferation
during low pH stress. Furthermore, we find that inhibition of anaplerotic glutamine
metabolism results in an increase in ROS levels and a further reduction in proliferation
(Fig 5-6). Glutamine metabolism has the capacity of generating carbon, nitrogenous
sources, and NADPH for redox balance [108, 168]. Since various studies have shown
that there is increased expression of the transaminase enzymes driving non-canonical
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glutamine metabolism in PDAC due to oncogenic KRAS, we predict that oncogenic
KRAS plays a significant role in metabolic reprograming in low pH stress. The pH of the
tumor microenvironment is heterogeneous while our experiments maintained a
homogeneous pH value, there may be additional differences in the metabolic phenotype
that correlates with the pH value inducing cellular stress we have seen here. Our
findings may have implications to future therapeutic approaches since we have
discovered the metabolic pathways the extracellular pH of the tumor microenvironment
can modulate in pancreatic cancer cells. Our data may provide new targets to synergize
with other known therapies for pancreatic cancer and increase therapeutic effectiveness
against PDAC.
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Chapter 2 Figures
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Figure 1A. PDAC cell growth is inhibited with decrease in pH of DMEM medium.
(A) Survival of S2-013 and Capan-1 PDAC cells cultured under conditions of varying pH
of culture media by MTT assays. These growth curves show that cells are not viable in
pH values bellow 7, which was then used to establish chronic low ph. Fig. 1A values
were normalized to control pH 7.4 (physiological pH value) at 72 hours of growth. Error
bars represent mean ± S.E.M. from at least three different samples. Two-way ANOVA
with Bonferroni post-test analysis was used for Fig. 1A to compare growth in low pH
versus physiological pH.
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Figure 1B. PDAC cells have reduced clonogeneicity in chronic low pH. PDAC cell
lines were adapted for 14 days to chronic low ph. Subsequently, these cells were subcultured and a fraction was diluted to seed 200 cells in 6-well plate for 14 days in control
pH (7.4) and low pH (7.0). Cell numbers were normalized to that of the control pH 7.4
(physiological pH value). Error bars represent mean ± S.E.M. from at least three different
samples. A two-tailed Student's t-test was used to compare low pH and control pH with
p-values *p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 1C. Chronic low pH expossure decreases cell cycle progression of PDAC
cells. Cell cycle analysis of S2-013 cells in control and low pH shows a significant
increase of population in G1/G0 indicating reduced clonogeneic rate. Cell numbers were
normalized to that of the control pH 7.4 (physiological pH value). Error bars represent
mean ± S.E.M. from at least three different samples. A two-tailed Student's t-test was
used to compare low pH and control pH with p-values *p < 0.05, **p < 0.01, and ***p <
0.001.
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Figure 2A and 2B. PDAC cells in chronic low pH exposure shows a significant
decrease in hallmarks of Warburg effect metabolism. Compared to control cells,
cells cultured in chronic low pH have a significant decrease in glucose and lactate
release both of which are the quintessential hallmarks of Warburg effect metabolism as
shown by (A) 3H-glucose uptake and (B) lactate release using colorimetric assay and
LC/MS/MS analysis of extracellular metabolite extracts. Data is normalized to that of the
cells at control pH (7.4). Error bars represent mean ± S.E.M. from at least three different
replicates. A two-tailed Student's t-test was conducted to compare uptake/release in low
pH relative to control pH with p-values *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2C. PDAC cells in chronic low pH exposure shows a significant decrease in
glycolysis. Polar metabolites were extracted from S2-013 and Capan-1 cells cultured in
control and low pH. LC/MS/MS-based metabolomics was used to quantify glycolysis
metabolites showing a significant decrease in glycolysis metabolic flux in low pH culture
conditions.
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Figure 2C. TCA cycle metabolic flux is maintained in chronic low pH. Polar
metabolites were extracted from S2-013 and Capan-1 cells cultured in control and low
pH. LC/MS/MS-based metabolomics was used to quantify TCA cycle metabolites
showing that unlike glycolysis TCA metabolism is not down regulated. Data in bar charts
is normalized to the values for the control pH (7.4). Error bars represent mean ± S.E.M.
from at least three different samples. A two-tailed Student's t-test to represent this data
with p-values *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3B, 3C. PDAC cells in chronic low ph show a significant increase of
glutaminolysis. Compared to control pH, PDAC cells in chronic low ph show a
significant increase in glutamine uptake and intracellular ATP levels as shown by 3Hglutamine uptake and bioluminescent assay to determine ATP levels in cell lysates.
Error bars represent mean ± S.E.M. from at least three different samples. A two-tailed
Student's t-test was conducted to compare these data sets with p-values *p < 0.05, **p <
0.01, ***p < 0.001.
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Figure 3D. PDAC cells in chronic low ph increase use of oxidative

phosphorylation. Cells cultured in low pH show a marked decrease in survival upon
oligomycin treatment. Oligomycin inhibits complex V of the electron transport chain.
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Figure 4 A. Metabolic flux through non-canonical anaplerotic glutamine
metabolism is enhanced in chronic low ph. (A) LC/MS/MS-based metabolomic
analysis of non-canonical glutamine metabolism in control (7.4) and low pH (7.0) culture
conditions shows increased metabolic flux through the glutamate transaminase-driven
pathway. Data in bar charts is normalized to the values for the control pH (7.4). Error
bars represent mean ± S.E.M. from at least three different replicates. A two-tailed
Student's t-test was conducted to compare control versus low pH in Fig. 4A and B with
p-values *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4 B. Transcription of enzyme mediators of non-canonical anaplerotic
glutamine metabolism is increased chronic low ph. Quantitative real-time PCR
analysis of genes coding for enzymes involved in non-canonical glutamine metabolism in
cells cultured under control and low pH. Data shows an increase of transaminase
enzymes and malic enzyme both of which are mediators of non-canonical glutamine
metabolism. Data in bar charts is normalized to the values for the control pH (7.4). Error
bars represent mean ± S.E.M. from at least three different replicates. A two tailed
Student's t-test was conducted to compare control versus low pH in Fig. 4A and B with
p-values *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4C and 4D. PDAC cells cultured in low pH conditions are more sensitive to
inhibition of glutamine metabolism. Treatment of S2-013 and Capan-1 cells to
treatment with aminooxyacetic acid (AOA; C) and to epicogallocatechin gallate (EGCG;
D) in control and low pH conditions shows increased sensitivity to glutamine metabolism.
However, cells in low pH are more sensitive to inhibition of the anapleurotc pathway.
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Figure 4E. PDAC cells cultured in low pH conditions are more sensitive to
inhibition of glutamine metabolism. Figure 4E shows a schematic illustration of
potential metabolite flow of glutamine in low pH culture conditions. The bold arrows
denote the metabolic flux of glutamine through the non-canonical pathway. Glutamine is
metabolized by glutamate synthase (GLS) and converted to glutamate, which is then
metabolized by glutamate dehydrogenase (GLS1) and/or glutamic oxaloacetic
transaminase 2 (GOT2). Subsequently, aspartate is metablized by glutamic oxaloacetic
transaminase 1 (GOT1) to oxaloacetate, which is converted to malate and then to
pyruvate by the malic enzymes. GOT1 expression is enhanced by oncogenic KRAS and
Malic Enzymes are critical fro NADPH production for redox homeostasis.
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Figure 5A, 5B, and 5C. Knockdown of GOT1 inhibits growth of PDAC cells in low
pH. (A) Western blotting to confirm the knockdown levels of GOT1 in S2-013 with two
independent targets by utilizing lentiviral delivery. Cell growth of GOT1 knockdown and
scrambled-control (shScr) cells in control pH (B) and low pH (C). GOT-1 knockdown
significantly reduces cell growth in both culture conditions, but cells in low pH are
severely impaired. A two-way ANOVA analysis, followed by Bonferroni posttests, was
conducted to compare growth curves with p-values *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5D and 5E. GOT1 depletion further increases intracellular ROS levels in low
pH culture. Fig. 5D shows measurement of intracellular ROS using carboxy-H2DCFDA
in control and low pH showing that ROS levels are higher in low pH culture.
Furthermore, GOT1 knockdown leads to increase ROS levels in both control in low pH,
but increase of intracellular ROS is much greater in low pH knockdown cells. Fig. 5E
shows the measurement of intracellular ROS of cells in low pH by staining with carboxyH2DCFDA (DCFDA) and staining with CDCFDA, a ROS-insensitive dye. The ROSinsensitive compound was used to show fluorescence was not an artifact of cell culture
using hydrogen peroxide treatment as a positive control as it induces ROS. The
experiment shows that CDCF stain does not detect ROS levels. Data in bar charts is
normalized to the values for the control pH (7.4). A two-way ANOVA analysis, followed
by Bonferroni posttests, was conducted to compare different treatments represented on
all the other panels with p-values *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5F-5K. GOT1-mediated anaplerotic glutamine metabolism produces NADPH for
ROS homeostasis. Fig. 5F LC/MS/MS measurement of NADP/NADPH and GSSG/GSH ratios in
control and low pH culture shows similar NADP/NADPH ratio, but the GSSG/GSH ratio is higher
in low pH culture indicating deregulation in NADPH mediated ROS suppression. Figures G to K
show quantitative real-time PCR analysis of genes coding for enzymes involved in ROS
regulation through oxidation of NADPH. Here it is observed that in low pH transcription of NADPH
oxidases (NOX) increases. NOX enzymes oxidize NADPH producing superoxide as a by-product
and super oxide dismutase (SOD) removes super oxides by combining it with protons and
producing hydrogen peroxide, which is then removed by reduced glutathione (GSSG-ox or GSHred) through GSH peroxidase or catalase, which is unchanged in low pH (data not shown). This
data implies ROS suppression occurs is of high priority in low pH. Data in bar charts is
normalized to the values for the control pH (7.4). A two-way ANOVA analysis, followed by
Bonferroni posttests, was conducted to compare different treatments represented on all panels
with p-values *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 6. Non-canonical glutamine metabolism regulates growth in chronic low ph.
Growth kinetics of scrambled control, and GOT1 knockdown cells cultured in low pH
media supplemented with N-acetyl cysteine (NAC), non-essential amino acids (NEAA),
or oxaloacetate (OAA). OAA is the product of the reaction carried by GOT1. This
experiment shows that growth is of knockdown cells in low pH is rescued by
supplementing OAA and ROS-quencher NAC suggesting the significance of metabolic
flux through GOT1 for ROS homeostasis. A two-way ANOVA analysis, followed by
Bonferroni post-tests, was conducted to compare different treatments with p-value *p <
0.05, **p < 0.01, ***p < 0.001.
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Figure 6B and 6C. Non-canonical glutamine metabolism regulates ROS levels in
chronic low ph. Fig. 6B colony formation of control and GOT1 knockdown cells
supplemented with NAC and OAA shows rescue of clonogeneicity upon pathway rescue
(OAA) and ROS quenching (NAC). Fig 6C shows suppression of intracellular ROS levels
in control and GOT1 knockdown cells supplemented with OAA and NAC, using H2O2 as
a positive control. Data in bar charts is normalized to the values for untreated scrambled
control. Error bars represent mean ± S.E.M. from at least three different replicates. A
two-way ANOVA analysis, followed by Bonferroni post-tests, was conducted to compare
different treatments with p-value *p < 0.05, **p < 0.01, ***p < 0.001.
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Summary of Work
Summary of Thesis:
Upon malignant transformation, PDAC cells modify their environment through
activation of PSCs leading to the desmoplasia and the collapse of normal tissue
vasculature that is replaced by the disorganized tumor vasculature. These changes in
TME favor growth of cancer cells as the hypoxic microenvironment activates HIF
inducing metabolic reprogramming that facilitates growth through up-regulation of
glycolysis. Similarly, oncogenes such as KRAS promote increased uptake of glucose
and glutamine, which are metabolized to produce energy, biomass, and co-factors for
redox reactions. Collectively, HIF activation and oncogenes cause Warburg effect
metabolism that is characterized by increased glucose uptake and its conversion to
lactate and protons, glutamine can be converted to lactate as well. The increased
metabolic rate of cancer cells results in accumulation of protons in the TME.
Interestingly, consistent measurements of intracellular and extracellular pH of growing
cancer cells show that pHi is alkaline and pHe is acidic. Decrease in pHi has been
shown to result in growth inhibition and apoptosis, while acidic pH e has been shown to
promote acidosis through activation of extracellular proteases that degrade ECM.
Based on these observations, the role of acidosis in carcinogenesis is being redefined
from a collateral effect of up-regulated metabolism to a hallmark of cancer.
However, the disorganized vasculature of tumors becomes an inefficient method to
vent metabolic acids from the TME. This creates a paradox as cancer cells require a
high metabolic rate to proliferate, but further disparity in the proton gradient between
the cytosol and the extracellular space of cells, which will prevent efficient proton
efflux from the cytosolic compartment thereby lowering pHi. Cancer cells cannot
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withstand cytosol acidification because excess protons will affect the ionization of
protonatable residues of amino acids in proteins thereby affecting their normal
function. Thus, maintenance of the aforementioned pH gradient is critical for survival
of cancer cells. For this reason cancer cells have developed complex mechanisms to
regulate pH through active transport of charged molecules across the plasma
membrane. Based on the pH challenge PDAC cells experience in the TME, I
hypothesized that further survival of PDAC cells is through selection of mechanisms
allowing cells to regulate metabolism or reprogram their metabolism in order to satisfy
pH homeostasis. To this end I replicated chronic acidification similar to tumor
conditions and demonstrated that chronic low ph causes growth inhibition likely due to
increased ROS levels. In this low pHe conditions, it was demonstrated that cells
survive by reprogramming their metabolism by enhancement of anapleurotic
glutamine metabolism at the expense of reducing glycolytic rate. The pathway is
enhanced by oncogenic KRAS expression and it serves the purpose of generating
energy for cellular homeostasis, as well as, providing the cells with NADPH for redox
control.
Conclusions based on experimental evidence and extant literature:
In vivo venting of protons depends on the proximity of cells to blood vessels
where the blood buffer system can remove excess protons. Therefore, the TME of
PDAC will contain cells far away from the blood vessel where cells survive by
activation of HIF response, which will cause an increase in dumping of protons onto
the extracellular space. Absolute oxygen deprivation will kill the cells; thus, cells must
be selected to move to gain oxygen access. At the same time, cells in the most
hypoxic or oxygen deprived region will secrete excess protons into the extracellular
space and the slow movement of protons toward the blood vessel will create the most
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acidic region of the tumor. Cells in the most acidic part of the tumor will have to
reprogram their metabolism in order to produce less protons, as their capacity to vent
protons from the cytosol will be reduced by the increased extracellular proton
gradient. Thus, a metabolic switch in which production of CO2 is increased will be
more favorable because CO 2 can passively diffuse across the plasma membrane.
This metabolic shift is likely supported by several mechanisms, including the
expression of nuclear respiratory factor 1, NRF1, that enhances mitochondria
function, increase in expression of the isoform of cytochrome c oxidase subunit 4
isoform 1 change to isoform 2, COX4I1 to COX4I2, and mitochondria cristae remodeling
to optimize ETC efficacy in low oxygen conditions [197, 198]. In this way, cells that can
adapt to acidosis of TME can survive by generating CO2 instead of protons. Cells that
are more proximal to blood vessels, are driven to grow by increased expression of
oncogenes, loss of tumor suppressors, and abundance of nutrients. Thus, this cell
population experiences less selective pressure, but at the same time it bears the
cancer phenotype of uncontrolled growth that will lead to continuous acidification of
extracellular space. Thus, the cells closer to the nutrients exhibit Warburg effect and
their release of protons into the TME will decrease venting of protons produced by
cells further away from blood vessels. It is a common understanding that the most
aggressive cells in PDAC tumors develop in the most hypoxic region, which is likely to
be the most acidic as well [136]. Figure 1 summarizes these statements.

Role of TME acidosis in carcinogenesis
Metastasis
In the past two decades the correlation between acidic TME and metastasis
gained much needed interest leading to extensive studies of this relationship. Thus, it
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has been shown that decreased pHe promotes invasiveness by enhancing cytoskeletal
dynamics leading to modification of cancer cell polarization, as well as, increase in
proteolytic activity of TAMs and fibroblasts, as well as, activating ECM proteases
released by the cancer cells themselves [34, 199, 200]. Interestingly, the contrasting
alkaline pHi promotes cytoskeleton remodeling by enhancing the activity of several
acting binding proteins [201]. These observations were shown in vivo using intravital
microscopy by monitoring HCT-116 cells, which showed that the lowest pHe regions of
the tumor underwent more cytoskeleton remodeling and had the highest expression of
NHE1 in order to maintain alkaline pHi [201]. Activation of proteases by acidic pHe was
demonstrated to increase angiogenesis by liberating pro-angiogenic factors trapped in
ECM—at the same time this promoted metastasis of cancer cells by clearing path to the
vasculature [202]. Another feature of TME acidosis that has gained interest over the
years is the increase of stem cell markers in cells cultured in acidic pH medium [203].
Acid-induced stemness is not limited to cancer cells, as it has been demonstrated in
osteosarcoma and melanoma that the low pH of the TME increases the population of
mesenchymal stem cells, which contribute to tumor growth by secreting pro-tumorigenic
factors [204]. Based on these observations, the process of carcinogenesis requires
acidification of the TME, as it will continue selecting the most aggressive malignant
phenotype. In addition passive CO2 and H+ venting of protons and active transport of
protons, Gillies et al. demonstrated that the lysosme associated membrane protein 2,
LAMP2, is critical for breast cancer tumorigenesis because it relocates to the plasma
membrane to aid the process of TME acidification thereby enhancing metastasis [205].
These lines of experimental evidence highlight selection of acidic TME to further
promote carcinogenesis.
Acidosis induces autophagy
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Autophagy is a regulated cellular process through which dispensable organelles
and macromolecules are turned over for metabolic purposes within the same cell .
Pancreatic cancer cells show elevated autophagy under basal conditions and its
inhibition leads to increased ROS, elevated DNA damage, and oxidative metabolic
defects associated with mitochondria dysfunction [206]. As a result, inhibition of
autophagy results in significant growth inhibition of PDAC cell lines, orthotopic mouse
models, and genetic ablation of autophagy results in prolong survival in animal models.
These observations suggest that autophagy is a feature of PDAC carcinogenesis, unlike
other cancer types where autophagy is a last resource survival mechanism upon
therapy-induced stress. Interestingly, increase in autophagy markers was demonstrated
upon acidosis stress in breast cancer cell line MDA-MB-231 this phenotype was
reversed/diminished in vivo upon administration of sodium bicarbonate [207]. The role of
autophagy in acidosis stress was further elucidated in melanoma cells, which were
unable to survive acidic stress upon knockdown of ATG5, autophagy marker necessary
for the processes to take place [208]. Further studies have elucidated the role of pHi
acidification in inhibiting mTOR, which occurs by TSC complex acting as a pH sensor,
protonation of residues inhibit its activation of mTOR, and by decrease in leucine uptake
that activates mTOR mediated inhibition of autophagy [209, 210]. The role of mitophagy
in acidosis may be just as essential for cell survival, as the mitochondria are critical for
metabolic reprograming necessary to survive in low pH stress and functional
mitochondria are required for metabolic reprogramming necessary to survive acidosis
stress [211]. Similarly, functional autophagy requires the acidification of autolysosomes
that achieve it through expression of V-ATPases allowing them to remove protons from
the cytosol into the lysosome vesicle [212]. The transformation of autophagy from a
tumor suppressive mechanism in normal cells into a pro-tumor mechanism in PDAC may
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be a consequence of cancer cell pH dynamics. These observations further highlight the
role of acidosis in PDAC carcinogenesis.
Acidosis of TME leads to immune suppression
Several lines of evidence show that acidification of the TME affects the antitumor immune response as exposure to lactate and protons decreases T-cell production
of IL-2, IFNγ, perforin, and granzyme B, as well as, inhibiting TNF release by monocytes
[213, 214]. Metabolomic analysis showed that low pH abrogates glycolysis in T-cells
causing inhibition of cytokine synthesis. Similarly, it has been shown that the decreased
immune response due to lowering pHi prevents increased expression of nuclear factor of
activated T-cells, NFAT, in NK cells and T-cells [215]. Studies showing the relationship
between the metabolic rate of cancer cells and its effects on T-cells in the TME showed
that T-cells deprived of glycolysis were unable to regulate NFAT-Ca2+ signaling to elicit
an immune response [216]. This was denoted by the low levels of PEP that were
corrected by overexpression of PEP carboxykinase, PCK, which allowed the cells to
utilize oxaloacetate to make PEP and re-establish glycolysis [216]. Similar observations
have been made upon ablation of LDHA, resulting in lower TME levels of protons and
lactate. Thus, cancer cells in the TME inhibit immune response by outcompeting immune
cells for nutrients and by exposing them to a low pHe, which induces metabolic
reprogramming to oxidative phosphorylation thereby inhibiting glycolysis-NFAT signaling
that allows for production of cytokines. These observations further highlight the
dependency of carcinogenesis in TME acidosis.

pH Sensing
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It is estimated that the acid load in the extracellular space of tumors is up to 10
times higher than in the cytosolic compartment and can lead to pH change of up to 1 pH
unit [217]. As I have previously described, excess protons are vented through the
bicarbonate buffer system aided by blood and kidneys. However, it is predicted that long
venting distances of more than 50µm will result in chronic low ph [217]. The most
extensively studied pH sensors in the plasma membrane are G-protein coupled
receptors, GPCRs, GPR4, OGR1, TDAG8, and G2A [218]. GPR4 stimulated by acidosis
has been reported to activate the Gs G12/13 pathways that increase cAMP levels and
activate Rho-Gef pathways for induction of cell migration respectively [219]. Low levels
of GPR4 in mouse models of melanoma results in impaired tumor growth and
impairment of angiogenesis [218, 220]. Overexpression of OGR1 has been shown to
inhibit metastasis in PC3 prostate cancer cells and in HEY ovarian cancer cells by
increasing adhesion to several ECM proteins [218, 220, 221]. TDAG8 has been shown
to increase tumor growth in Lewis lung carcinoma with similar findings shown in animal
models using NCI-H460 non-small cell lung cancer cell line with knockdown of TDAG8
showing reduced survival in acidic conditions of tumor [219, 222]. TDAG8 activation by
acidosis has been demonstrated to inhibit apoptosis upon nutrient starvation and its
overexpression leads to transformation of mammary epithelial cells in vitro [219, 222].
Interestingly, in lymphoma high levels of TDAG8 has been shown to inhibit c-Myc
expression thereby showing the ability of pH sensing to affect master regulators of
metabolism [222]. G2A signaling is known to affect pH growth by inhabiting G2/M cell
cycle progression resulting in mitosis inhibition [218]. Understanding the mechanisms of
pH sensors will provide better insight into the molecular basis of pH-dependent survival
of cancer cells in acidic TME by allowing us to understand their behavior in acidosis and
eventually identify new diagnostics and therapeutics.
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Although pH affects many cellular processes, one of the most sensitive systems
in the cells is the actin cytoskeleton, which through its assembly and disassembly it
determines vesicle trafficking, contraction, migration, invasion, and metastasis [57].
Interestingly, de novo trafficking assembly requires alkaline intracellular pH this process
is greatly affected by decreasing the pHi. This highlights the significance of alkaline pHi
as the cells will cease a lot homeostatic functions performed by the cytoskeleton if the
pH drops. For example, cofilin requires the de-phosphorylation of a N-terminal serine
and the deprotonation of a C-terminal histidine residue to de-polymerize filamentous Factin and begin the process of de novo actin polymerization [223]. Thus, in cell trafficking
cells need a higher cytosolic pH to re-assemble and dis-assemble actin filaments.
Similarly, it has been demonstrated that the leading edge of focal adhesions in migrating
cells has a higher pHi this process is mediated by talin binding to F-actin in focal
adhesions and that talin binding of F-actin filaments decreases if pHi drops bellow 7.2
[223]. This is due to protonation of amino acids that cause a conformational change in
talin that prevents interatcition with F-actin filaments. Interestingly, binding of cofilin and
GEFs with plextrin-homology domains to phosphoinositides has been shown to be pH
dependent [143, 223]. A common feature of phosphoinositide recognition domains is that
at lease one histidine is contained within the recognition domain this has not been
shown experimentally, but proteins with this domain may be pH sensitive for membrane
localization [143]. Thus, understanding the significance of pH-dependent histidine
switches can help to understand pH dependent cytoskeleton function.

Targeting Phi Regulation For Therapy
TME acidosis creates a challenge in cancer therapy
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Neutral molecules can pass freely through the plasma membrane, but the
passage of charged compounds depends on extracellular pH—this phenomenon is
known as ion trapping [57]. The acidic TME of tumors is unfavorable to weak base
chemotherapeutic agents such as paclitaxel because they will be protonated. Thus, it
is estimated that if the pH difference between the intra and extra cellular
compartments is 1 pH unit there will be a ten-fold negative difference in weak base
concentration in the cytosol [224]. Conversely, the more acidic chemotherapeutic
agents such as cisplatin will localize to the alkaline intracellular environment of cells.
These phenomena calls for intervention through proton pump inhibitors in order to
control extracellular pH and predict better delivery of therapeutic agents.
Neutralization of pHe using systemic buffers such as NaHCO3 has been proposed in
efforts to identify which therapeutic modalities to take advantage of TME
neutralization [225]. Indeed, bicarbonate treatment in hepatocellular carcinoma
increases the efficacy of weak base chemotherapeutic agents [226]. Interestingly, this
approach does not affect growth of the primary tumor, but it has been observed to
reduce metastasis in animal models. Furthermore, bicarbonate treatment has also led
to improved immunotherapy response by increasing response to anti-PD1 and antiCTLA4 in melanoma mouse models [227]. The immunotherapy response can also be
improved by inhibition of V-ATPases with proton pump inhibitors [228]. This
observation was also shown in spontaneous mouse models of prostate
adenocarcinoma where bicarbonate buffer treatment at 6-weeks of age, prior to tumor
formation, resulted in lost of tumor formation and delay of tumor formation [229].
These studies highlight the significance of acidic pH e in carcinogenesis. Addition of
exogenous buffers may have adverse physiological effects, as it will lead to systemic
pathologic alkalosis [225]. Therefore, instead of targeting the pH e with buffers pHsensitive drug delivery systems have been developed. These molecules include
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peptides, liposomes, micelles, and polymeric nanoparticles [224, 230]. pH-lowinsertion-peptides, pHLIPs, have been used to image PDAC tumor progression in vivo
and ex vivo [231]. Thus, these molecules transport drugs to cancer cells through
encapsulation or by chemical conjugation. These molecules work by having increased
stability in physiological pH conditions and destabilizing or fusogenic in low pH
environment [224, 230]. In this way, delivery to cancer cells in acidic TME is ensured
and the viability of drugs is enhanced, as sequestration or inactivation during
transport to tumor tissue will be diminished.
Inhibition of cancer pH i regulation
Proton-pump-inhibitors (PPI) are pro-drugs that are activated by low pH
generating sulfenaminde therefore in the acidic gastric environment or in TME they
become activated and covalently interact with sulfhydryl groups of cysteine residues
of V-ATPases inhibiting their activity [232]. These compounds have reached advance
clinical trials as they have demonstrated to suppress tumor growth in mouse models
and prevent acid-induced therapy resistance caused by ion trapping effect. Another
target for therapy, are the carbonic anhydrases, CA, particularly CAIX and CAXII that
are overexpressed in many tumor types compared to normal tissue [233]. Indeed,
CAIX positive staining is an indicator of poor prognosis in PDAC [234]. Interestingly,
CAs distribution in tumor tissues show increased expression of CAIX in the tumor
edge and CAXII occurring more in the tumor center [235]. These observations have
led to the development of specific CA inhibitors, which have shown to be potent
growth inhibitors of primary tumor and metastases evidenced in mouse models. For
this reason antibodies and small molecule inhibitors of CAs are currently undergoing
clinical trials [236]. Monocarboxylate transporters, MCTs, which conduct the inward
and outward transport of protons and lactate from cytosol to extracellular space, are
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also a reasonable therapeutic target [237]. The MCT1,2 inhibitor AXD3965 has
shown potent anti-tumor effects in mouse models and is currently undergoing clinical
trials [238]. More advantageously is the development of inhibitors for hypoxia specific
MCT4; to this end, it has been reported that the drug diclofenac inhibits lactate efflux
in cancer cells independently of inhibition with cyclooxygenase [239]. Another obvious
target for disruption of pH regulation in cancer cells is the inhibition of sodium
hydrogen exchanger, NHE1, but no clinical break through has been achieved. This
has been shown by knockdown of NHE1 and treatment with NHE1 selective
pharmacological inhibitors amiloride and cariporide that show extensive anti-cancer
effects in vivo [240]. However, side effects of pharmacological inhibition of NHE1
include myocardial infarction. Lastly, inhibition of sodium bicarbonate transporters,
NBCs, is also a likely target to disrupt pH homeostasis. To his end, NBC specific
compounds S0859 and S3705 have been used in vitro showing growth inhibition in 3D
spheroid models and breast cancer cell lines [241].
Inhibition of pH regulation shows exceptional results in preventing further
growth of tumors, but only a few compounds have reached clinical trials and they
have delivered disappointing outcomes due to aberrant side effects. For example,
MCT inhibitors are severely limited by the physiological role of the lactate shuttle in
the brain or the overexpression of NHE1 in cardiac tissue [242, 243]. Another
alternative is the dynamic nature of cancer, which upon selective pressure would lead
to evolution of a compensatory mechanism with expression of different pH regulating
proteins or reprogramming metabolism to produce less acids. To this end, new exiting
data fro Grillo-Hill et al. shows that inhibition of proton cytosolic efflux in combination
with up-regulation of oncogenic RAS expression is lethal for growing cells in
Drosophila models [243]. These studies were also confirmed in cancer cells with
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increased oncogene expression. Perhaps, a major break through could occur in the
future with advancement in tumor imaging allowing for visualization of acidic regions
of the tumor, which would make it easier to determine therapeutic approach.

Conclusion & Future Directions
Oncogenic KRAS drives metabolic response to acidosis
In chapter 1 of this thesis I’ve described the somatic evolution of pancreatic
ductal cells into PDAC and concluded that malignant transformation is a slow process
limited by tissue-mediated growth inhibition and dependent on metabolic substrate
uptake. To this end, malignant cells gain oncogenic KRAS mutation and develop loss
of function in tumor suppressors TP53 and CDKN2A, which leads to unrestricted
growth. The combination of intermittent hypoxia and oncogene expression in PDAC
cells promotes growth and generation of an acidic TME. However, in order to sustain
the cancer phenotype, PDAC cells must maintain alkaline pHi and acidic pHe pH
dynamics, as deviation from this will be in detriment of growth and overall
homeostasis of the cells. In order to regulate pH, cancer cells have developed active
transport of protons into the extracellular space because increased pH e will impair
passive transport of metabolic acids. This creates a paradox for cancer cells, as
further growth will be detrimental for pH balance. Thus, I hypothesized that further
tumor progression depends on pH regulation and metabolic reprograming to meet
homeostatic demands. In chapter 2, I conducted several experiments to determine the
metabolism of PDAC cells in chronic low ph. Here, I identified that chronic low ph
reduced proliferation rate and the cancer cells rely more on oxidative metabolism
instead of glycolysis for survival. This metabolic phenotype is supported by increased
glutamine uptake. Glutamine is metabolized through the non-canonical glutamine
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anapleurotic pathway, which allows the cells to produce pyruvate for decarboxylation
reactions and ATP synthesis through ETC, as well as, NADPH that is useful for redox
balance. This pathway shows metabolic reprogramming under chronic low ph that will
favor biomass production, redox balance, and energy production. Most significantly,
this pathway is possible because oncogenic KRAS increases the expression of GOT1
and inhibits GLS1, which will lead to redirection of glutamine metabolism to the
anapleurotic pathway. In non-acidosis conditions, the same pathway is essential for
redox balance and growth, because NADPH production through anapleurotic
glutamine metabolism compensates for lack of NADPH production from oxidative
PPP. KRAS driven PDAC tumors are known to bypass oxidative PPP in order to
accelerate rate of non-oxidative PPP to generate nucleic acids for cell replication.
Therefore, oncogenic KRAS appears to be a critical regulator of cellular homeostasis
in stress conditions by inducing metabolic reprogramming.
Future Directions
The observations by Grillo-Hill et al. confirm our hypothesis that up-regulated
metabolic rate without means to regulate pH dynamics results in cell death. However,
targeting pH regulation has been shown to be detrimental due to side effects of
treatment, as all biological processes depend on pH regulation. Thus, one important
avenue of research is to understand the signaling mechanisms allowing cancer cells
to undergo metabolic reprogramming and membrane expression of pH regulating
proteins. The pathways mediated by GPCRs and non-GPCR extracellular sensors
have not been completely elucidated. Furthermore, known GPCR signaling is known
cause inhibition of cytoskeleton remodeling not pH regulation per se. This is
demonstrated by overexpression of GPR4 and OGR1 in cancer cells, which results in
growth inhibition and invasiveness. This is likely because over-expression of pH
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sensitive GPCRs will require less pHe disturbances to alert the cytosol of acidosis
stress conditions and inhibit cytoskeleton remodeling [218]. While metabolic
reprogramming and proton efflux would not be affected because the pH gradient is
not changing; alternatively, the response can be induced by epigenetic changes as it
has been demonstrated in HeLa cells that low pHi favors histone de-acetylation and
alkaline pHi favors acetylation of histones [244]. Another interesting study to
understand the evolution of pH dynamics in cancer is to evaluate somatic mutations,
which occur randomly and may cause deleterious or advantageous alterations to gene
function. However setting that gene product mutations aside, an interesting study
regarding amino acid mutations landscape by Szpeech et al. shows that the
predominant mutations in many solid tumors are that of arginine to histidine [245]
[246]. These analyses predict that arginineàhistidine mutations occur in nearly 50%
of the samples analyzed. This mutation is of particular interest for pH i regulation
because of the role of histidine switches in actin remodeling control mechanisms due
to acidic pHi response. Furthermore, increase in histidine amino acid residues will
result in an increase buffer capacity since the pKa of histidine is around 6.5 and
arginine is ~12, thus histidine will be able to titrate narrow pH changes [247].
Interestingly, p53 is one of the most studied molecules in cancer research because of
its R273H mutation, which has been shown to be pH sensitive in a study by White et
al. where it was demonstrated that arginineàhistidine had increased transcriptional
activity in low pHi [246]. Thus, protonation of histidine will promote interaction with the
phosphate backbone of DNA enabling transcription of p53 response genes. Further
studies are required to elaborate more on the role of somatic mutations and their role in
pHi regulation, as well as, the pH-induced posttranslational modifications and
subsequent phenotypic alterations. Based on the observations made throughout this
document, future perspectives in cancer therapy should take in consideration the
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biologic significance of pH dynamics in order to determine better therapeutic
approaches.
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Chapter 3 Figures
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Figure 1. Hypothetic metabolic-pH relationship in PDAC tumors. The metabolism of
PDAC cells is defined by the oncogenic KRAS and oxygen availability. PDAC cells that
are proximal to blood vessels can undergo rapid growth because pH dynamics are not
affected due to rapid venting of protons and CO2. This is the classic Warburg effect seen
during in vitro PDAC cell culture. Cells further away from blood vessels experience
chronic low ph because proton venting is limited by growth of cells nearer to the
vasculature. In addition, excess release of CO2 and CA expression will convert it to
carbonic acid, which may generate more protons and bicarbonate to buffer pHi of cells
undergoing acidosis stress. Cells that are the most distal from vasculature undergo
hypoxia driven metabolic reprogramming that will further exacerbate acid load into the
TME. Thus, cells closest to the hypoxic region will experience the most stress from TME
acidosis.
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